<html><head>
		<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
	    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no">
	    <meta name="format-detection" content="telephone=no">
	    <meta name="apple-mobile-web-app-capable" content="yes">
	    <meta name="apple-mobile-web-app-status-bar-style" content="black"> 
	    <meta http-equiv="x-ua-compatible" content="IE=11,10,9,8">
	    <title>Jiangsu Hengrui Pharmaceuticals Co., Ltd. </title>
	    <meta name="keywords" content="恒瑞医药、制药企业、创新药、注射剂、口服制剂、吸入性麻醉剂">
    	<meta name="description" content="恒瑞医药是一家从事创新和高品质药品研制及推广的民族制药企业，已发展成为国内知名的抗肿瘤药、手术用药和影像介入产品的供应商。2020年，公司入选全球投行Torreya公布的全球1000强药企榜单，位列第21位。在美国制药经理人杂志（PharmExec）公布的2021年全球制药企业TOP50榜单中，恒瑞医药排名连续三年攀升，位列第38位">
    	
    	<script src="https://hm.baidu.com/hm.js?7ed5119f68d6d3b663540b65ce571722"></script><script language="javascript" type="text/javascript" src="/en/js/jquery-3.5.1.js"></script>
    	<script language="javascript" type="text/javascript" src="/en/js/global.js"></script><link rel="stylesheet" type="text/css" href="//at.alicdn.com/t/font_2613794_d5zzfhu8n2w.css">
    	
    	<link href="/en/css/global.css" rel="stylesheet" type="text/css">     	
    	<link href="/en/css/max800.css" rel="stylesheet" type="text/css">
    	<link href="/en/css/swiper.css" rel="stylesheet" type="text/css">
    	<link href="/en/css/step.css" rel="stylesheet" type="text/css">
    	<link href="/en/css/aos.css" rel="stylesheet" type="text/css"> 
    	
    	<script type="text/javascript">
            var Column = 2;
    	</script>
    	   	
	</head>
	
	<body class="bgf5f5f5" aos-easing="ease" aos-duration="1000" aos-delay="0">
		<!--手机端菜单-->
	    <div id="cd-lateral-nav"><link rel="stylesheet" href="/en/css/mobile-menu.css">

<script src="/en/js/mobile-menu.js"></script> 
<script>
jQuery(document).ready(function () {
    jQuery('header nav').meanmenu();
});
</script>

<header>
	
	<nav>
		<a href="/en/index.html" class="dis mobile-logo"><img src="/en/images/logo.png" class="dis marginauto"></a>
		<div class="language fright">
			<a href="/index.html" class="language-a border-radius2">中</a>
			<span class="language-span border-radius2">EN</span>
	</div>
		<ul>
			<li>
				<a href="/en/index.html">Home</a>	
			</li>	
			<li>
				<a href="/en/about.html">About us</a>	
			</li>	
			<li>
				<a href="/en/pipeline.html">Pipeline</a>	
			</li>					
			<li>
				<a href="/en/partnering.html">Partnering</a>	
			</li>	
			<li>
				<a href="/en/media/index.html">Media</a>	
				<ul>
					<li><a href="/en/media/index.html">News</a></li>
					<li><a href="/en/media/publication.html">Publications</a></li>
				</ul>
			</li>
			<li>
				<a href="/en/investor.html">Investor</a>	
			</li>
		</ul>
	</nav>
</header>
</div>
	    <!--手机端菜单end-->
		<section class="headbox elCurrent"><div class="navbox mo_undis cf">
	<a href="/en/index.html" class="dis logo"><img src="/en/images/logo.png" class="dis height100"></a>
	<script type="text/javascript">
		$(document).ready(function () {if (window.devicePixelRatio > 1) {var images = $(".logo img");images.each(function(i) {var x1 = $(this).attr('src');var x2 = x1.replace(/(.*)(\.\w+)/, "$1@2x$2");$(this).attr('src', x2);});}});
	</script>
		
	<div class="language fright">
			<a href="/index.html" class="language-a border-radius2">中</a>
			<span class="language-span border-radius2">EN</span>
	</div>
	<div class="nav fright">
		<ul class="cf">
			<li class="menuLi">
				<a href="/en/index.html" class="mainmenu">Home</a>	
			</li>	
			<li class="menuLi">
				<a href="/en/about.html" class="mainmenu">About us</a>	
				<!-- <div class="menuListBox">
					<a href="#!">公司资料</a>
				</div> -->
			</li>
			<li class="menuLi">
				<a href="/en/pipeline.html" class="mainmenu menuLipitchon">Pipeline</a>	
			</li>
			<li class="menuLi">
				<a href="/en/partnering.html" class="mainmenu">Partnering</a>	
			</li>
			<li class="menuLi">
				<a href="/en/media/index.html" class="mainmenu">Media</a>	
				<div class="menuListBox" style="height: 0px;">
					<a href="/en/media/index.html">News</a>
					<a href="/en/media/publication.html">Publications</a>
				</div>
			</li>
			<li class="menuLi">
				<a href="/en/investor.html" class="mainmenu">Investor</a>	
			</li>
		</ul>
	</div>
	
</div>	



<script>
function dropMenu(obj){
	console.log(Column,22222)

	var bname =$(".menuLi");

	$(obj).each(function(i,v){
	var theSpan = $(v);
	// console.log(v)
	var theMenu = theSpan.find(".menuListBox");
	var tarHeight = theMenu.height();
	//
	theMenu.css({height:0});
	theSpan.hover(
	function(){
		bname.find(".mainmenu").removeClass("menuLiBnameover");
		theSpan.find(".mainmenu").addClass("menuLiBnameover");
		theMenu.stop().show().animate({height:tarHeight},300);
	},function(){ 
			theSpan.find(".mainmenu").removeClass("menuLiBnameover");
			theMenu.stop().animate({height:0},100,function(){$(this).css({display:"none"});
			});
			$( bname[ Column ] ).find(".mainmenu").addClass("menuLipitchon");			
		});
	});
	$( bname[ Column ] ).find(".mainmenu").addClass("menuLipitchon");			
}
$(document).ready(function(){
	console.log(Column,11111)
	dropMenu(".menuLi"); 	
});


$(document).scroll(function(){
	var scrollTop = document.documentElement.scrollTop || window.pageYOffset || document.body.scrollTop;
	if(scrollTop > 0){
		$(".headbox").addClass("current");
	}else{
		$(".headbox").removeClass("current");
	}
})	
</script>
</section>
		<section class="headspace"></section>
		<article>
			<section class="width100 inv-kv pip-bg positionRelative">
				<div class="container">
				<div class="color1e55a8 poabsolute-h50 aos-init aos-animate" aos="fade-up">
                <p class="bigtitle">Pipeline</p>
                <h4 class="paddingtop20 mo_area_70">Pipeline highlights as of April 2022</h4>
                </div>
				</div>
			</section>
			<section class="block-padding-t60 container mo_paddingtop40 aos-init aos-animate" aos="fade-up">
				<div class="cf">
					<h3 class="paddingbottom30">Therapeutic areas</h3>
					<div class="pip-tab bgfff cf tcenter">
					<div id="tabs">
						<a class="disinblock area_12 padding20" name="#tab1" value="1" id="current">All</a>
						<a class="disinblock area_12 padding20" name="#tab2" value="2">Oncology</a>
						<a class="disinblock area_25 padding20" name="#tab3" value="3">Cardiovascular &amp; Metabolism</a>
						<a class="disinblock area_12 padding20" name="#tab4" value="4">Autoimmune</a>
                        <a class="disinblock area_12 padding20" name="#tab5" value="5">Pain</a>
						<a class="disinblock area_15 padding20" name="#tab6" value="6">Anti-infection</a>
						<a class="disinblock area_12 padding20" name="#tab7" value="7">Other</a>
					</div>
					</div>
				</div>
			</section>
			<section class="paddingtop10 container paddingbottom60 mo_paddingbottom40">
				<div id="content">
					<div id="tab1" style=""> <div class="row10 cf pipSeeLis mo_row">  <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this)">				<span class="dis cf">          <h4 class="fleft">SHR-1210 (camrelizumab)</h4>           <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">Anti-PD-1 Antibody</p>				</a>   <div class="padding20 bgfff miin-height">       <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>              <p class="area_20">II</p>             <p class="area_20">III</p>              <p class="area_20">NDA</p>             <p class="area_20">Launched</p>          </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(34, 174, 183); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(37, 166, 195); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 428px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative ">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 191, 45); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 180, 41); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 161, 36); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 214px;">
</div>
</div>
</div></div>     </div>  </div>   <div class="mo_dis">       <div class="pipShowlis paddingtop20 positionRelative">         <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">Programmed cell death protein (PD-1) is an immune checkpoint that guards against autoimmunity and prevents the immune system from killing cancer cells. Anti-PD-1 antibody blocks the interaction between PD-1 and PD-L1, activating the immune system to kill cancer cells. In recent years, PD-1/PD-L1 antibodies have become the backbone of immune oncology therapies. 
<br>
<br>Camrelizumab is an anti-PD-1 mAb approved in China in 2019. Camrelizumab is approved for the treatment of 1L NSCLC, 2L HCC, 2L EC, 3L r/r cHL, ≥ 2L NPC, and 1L NPC in China. Another 8 NDAs were submitted. According to Evaluate Pharma, camrelizumab is projected to be the 3rd best selling anti-PD-1 antibody worldwide, only after Keytruda and Opdivo. The user experience is highly positive in China.
<br>
<br>A total of 34 trials for camrelizumab are ongoing/completed. A global phase III clinical study of camrelizumab plus apatinib (VEGFR2 inhibitor) vs. sorafenib as the first-line therapy in patients with advanced hepatocellular carcinoma (HCC) is ongoing. FDA granted Orphan Drug Designation to camrelizumab for HCC. First BLA submission in the US/EU (1L HCC) is expected in Q4 2021.
<br>
<br>In April 2020, Hengrui Pharma licensed the Korean rights of camrelizumab to CrystalGenomics Inc., a biotech company based in the Republic of Korea.</p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick="pipClose(<i"></a></div></div>  </div></div>		</div>   <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this,2)">				<span class="dis cf">           <h4 class="fleft">SHR-1258 (pyrotinib)</h4>          <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">EGFR/HER2/HER4 TKI </p>			</a>  <div class="padding20 bgfff miin-height">      <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>            <p class="area_20">II</p>            <p class="area_20">III</p>            <p class="area_20">NDA</p>             <p class="area_20">Launched</p>           </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(34, 174, 183); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(37, 166, 195); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 428px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative  ">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 191, 45); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 180, 41); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 161, 36); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 214px;">
</div>
</div>
</div></div>     </div>  </div>  <div class="mo_dis">     <div class="pipShowlis paddingtop20 positionRelative">          <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Pyrotinib selectively and irreversibly inhibits the phosphorylation and downstream signaling of EGFR/HER2/HER4 tyrosine kinases. Pyrotinib received the marketing approval in China for the 2L treatment of relapsed or metastatic HER2-positive breast cancer in combination with capecitabine in July 2020. 
<br>
<br>A total of 21 clinical trials for pyrotinib are completed or ongoing, including 6 phase III trials for neoadjuvant, extended adjuvant, 1st line, and 2nd line treatment for HER2+ breast cancer in China, as well as a global phase III trial for HER2 mutant NSCLC (ongoing in ≥6 countries/regions).
<br>
<br>In September 2020, Hengrui Pharma licensed the Korean rights of pyrotinib to HLB Life Science Co., Ltd., a biotech company based in the Republic of Korea.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>			</div>		</div>  <div class="mo_undis">      <div class="area_100 pipShowlis padding10 positionRelative">         <div class="triangle-up"></div>         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>		</div>	</div> <div class="row10 cf pipSeeLis mo_row">  <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this)">				<span class="dis cf">          <h4 class="fleft">SHR3162 (fuzuloparib)</h4>           <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">PARP Inhibitor</p>				</a>   <div class="padding20 bgfff miin-height">       <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>              <p class="area_20">II</p>             <p class="area_20">III</p>              <p class="area_20">NDA</p>             <p class="area_20">Launched</p>          </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(34, 174, 183); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(37, 166, 195); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 428px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative ">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 191, 45); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 180, 41); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 161, 36); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 214px;">
</div>
</div>
</div></div>     </div>  </div>   <div class="mo_dis">       <div class="pipShowlis paddingtop20 positionRelative">         <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">Poly ADP ribose polymerase (PARP) is an enzyme that detects and initiates an immediate cellular response to metabolic, chemical, or radiation-induced single-strand DNA breaks. In BRCA1/2 mutated cancer cells, where the double-strand DNA break repairing function was damaged, the inhibition of PARP induces death of cancer cells but not normal cells. 
<br>
<br>Fuzuloparib received the marketing approval in China for the treatment of BRCA-mutated recurrent ovarian cancer in Dec 2020 and the maintenance treatment of recurrent ovarian cancer in June 2021. 
<br>
<br>Thirteen clinical trials for fuzuloparib have been completed, additional fourteen trials are ongoing including five phase III trials for ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer, and two phase Ib trials for TNBC and SCLC.  
<br>
<br>A global phase III trial is ongoing to study the combination of SHR3162, abiraterone and prednisone vs. abiraterone and prednisone for the 1L treatment of mCRPC in the US, EU, Australia and the Republic of Korea. </p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick="pipClose(<i"></a></div></div>  </div></div>		</div>   <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this,2)">				<span class="dis cf">           <h4 class="fleft">SHR-1316</h4>          <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">Anti-PD-L1 Antibody</p>			</a>  <div class="padding20 bgfff miin-height">      <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>            <p class="area_20">II</p>            <p class="area_20">III</p>            <p class="area_20">NDA</p>             <p class="area_20">Launched</p>           </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(34, 174, 183); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 321px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative  ">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 191, 45); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>  <div class="mo_dis">     <div class="pipShowlis paddingtop20 positionRelative">          <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> In many types of human tumors, programmed cell death ligand 1 (PD-L1) is highly expressed. Such high expression is often associated with poor prognosis. 
<br>
<br>SHR-1316 is a humanized IgG4 monoclonal antibody that binds specifically to human PD-L1, thereby interrupting the interaction of PD-L1 with PD-1 and B7-1 receptors. SHR-1316 is being developed for the treatment of solid tumors and hematologic malignancies. It demonstrated competitive anti-tumor efficacy and safety profiles in pre-clinical studies, as well as a desirable CMC profile. 
<br>
<br>The NDA of SHR-1316 in combination with chemotherapy for SCLC has been filed to NMPA. A phase I trial for solid tumors is ongoing in Australia. </p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>			</div>		</div>  <div class="mo_undis">      <div class="area_100 pipShowlis padding10 positionRelative">         <div class="triangle-up"></div>         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>		</div>	</div> <div class="row10 cf pipSeeLis mo_row">  <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this)">				<span class="dis cf">          <h4 class="fleft">SHR3680</h4>           <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">AR Antagonist</p>				</a>   <div class="padding20 bgfff miin-height">       <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>              <p class="area_20">II</p>             <p class="area_20">III</p>              <p class="area_20">NDA</p>             <p class="area_20">Launched</p>          </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(34, 174, 183); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(37, 166, 195); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 428px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative ">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 191, 45); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 180, 41); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 161, 36); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 214px;">
</div>
</div>
</div></div>     </div>  </div>   <div class="mo_dis">       <div class="pipShowlis paddingtop20 positionRelative">         <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">Androgen receptor (AR) is a ligand-dependent transcription factor. AR overexpression is identified as a frequent driver of castration-resistant prostate cancer (CRPC). AR plays a critical role in cell growth in CRPC despite low serum androgen levels. 
<br>
<br>SHR3680 is a second-generation full AR antagonist for prostate cancer without agonistic activity. It has shown promising efficacy in the control of bone metastasis, soft tissue lesions, and PSA level in phase I/II trial. Currently, a head-to-head phase III trial of SHR3680 + ADT vs bicalutamide + ADT for metastatic hormone-sensitive prostate cancer (mHSPC) is ongoing in China and Europe. Two phase II trials for mCRPC are ongoing in China. </p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick="pipClose(<i"></a></div></div>  </div></div>		</div>   <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this,2)">				<span class="dis cf">           <h4 class="fleft">SHR1020 (famitinib)</h4>          <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">VEGFR2/c-Kit/PDGFR</p>			</a>  <div class="padding20 bgfff miin-height">      <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>            <p class="area_20">II</p>            <p class="area_20">III</p>            <p class="area_20">NDA</p>             <p class="area_20">Launched</p>           </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 214px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative  undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>  <div class="mo_dis">     <div class="pipShowlis paddingtop20 positionRelative">          <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as major targets for drug discovery. Famitinib is a novel, multi-targeted receptor tyrosine kinase inhibitor with potential antineoplastic activity that primarily targets VEGFR2, c-Kit, and PDGFR.
<br>
<br>A phase III clinical trial of famitinib for gastrointestinal stromal tumors and another phase III trial of famitinib in combination with camrelizumab (anti-PD-1 antibody) and chemotherapy for NSCLC are ongoing in China. </p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>			</div>		</div>  <div class="mo_undis">      <div class="area_100 pipShowlis padding10 positionRelative">         <div class="triangle-up"></div>         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>		</div>	</div> <div class="row10 cf pipSeeLis mo_row">  <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this)">				<span class="dis cf">          <h4 class="fleft">SHR6390 (dalpiciclib)</h4>           <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">CDK4/6 Inhibitor</p>				</a>   <div class="padding20 bgfff miin-height">       <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>              <p class="area_20">II</p>             <p class="area_20">III</p>              <p class="area_20">NDA</p>             <p class="area_20">Launched</p>          </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(34, 174, 183); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(37, 166, 195); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 428px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>   <div class="mo_dis">       <div class="pipShowlis paddingtop20 positionRelative">         <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">Cyclin-dependent kinases 4 and 6 (CDK4/6) are key components of cell cycle progression and are dysregulated in certain cancers. Inhibition of CDK4/6 induces cell cycle arrest at the G1 phase, thus retards tumor growth. SHR6390 is a novel CDK4/6 inhibitor. SHR6390 received the marketing approval in China for the 2L treatment of HR+/HER2- locally advanced or metastatic breast cancer in combination with fulvestrant in January 2022.</p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick="pipClose(<i"></a></div></div>  </div></div>		</div>   <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this,2)">				<span class="dis cf">           <h4 class="fleft">SHR-1701</h4>          <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">Bifunctional fusion protein targeting  PD-L1 and TGF-β</p>			</a>  <div class="padding20 bgfff miin-height">      <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>            <p class="area_20">II</p>            <p class="area_20">III</p>            <p class="area_20">NDA</p>             <p class="area_20">Launched</p>           </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 214px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative  ">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 191, 45); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>  <div class="mo_dis">     <div class="pipShowlis paddingtop20 positionRelative">          <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Secretion of TGF-β and upregulation of immune checkpoint PD-L1 are two main contributors to immune evasion and tumor progression. SHR-1701 is an investigational bi-functional fusion protein composed of a mAb against PD-L1 fused to the extracellular domain of human TGF-β receptor II, designed to simultaneously block the two immunosuppressive signaling pathways commonly used by cancer cells. 
<br>
<br>SHR-1701 is currently in phase II for unresectable stage III NSCLC and pancreatic cancer in China. A global phase I clinical trial for advanced solid tumors is ongoing in China and Australia.
<br>
<br>In November 2020, Hengrui Pharma licensed the Korean rights of SHR-1701 to DONG-A ST CO., Ltd who now has exclusive rights to conduct clinical development, manufacture, and pursue commercialization licenses in the Republic of Korea.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>			</div>		</div>  <div class="mo_undis">      <div class="area_100 pipShowlis padding10 positionRelative">         <div class="triangle-up"></div>         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>		</div>	</div> <div class="row10 cf pipSeeLis mo_row">  <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this)">				<span class="dis cf">          <h4 class="fleft">SHR-1501</h4>           <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">IL-15 and IL-15 Rα/Fc Fusion Protein</p>				</a>   <div class="padding20 bgfff miin-height">       <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>              <p class="area_20">II</p>             <p class="area_20">III</p>              <p class="area_20">NDA</p>             <p class="area_20">Launched</p>          </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>   <div class="mo_dis">       <div class="pipShowlis paddingtop20 positionRelative">         <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">IL-15 induces proliferation and activation of natural killer cells and CD8+ T cells to activate both innate and adaptive immunity to enhance patients’ immune response against the tumor. Meanwhile, IL-15 neither stimulates Treg proliferation, nor promotes activation-induced T-cell death. 
<br>
<br>SHR-1501 is an IL-15 super-agonist to boost the immune system. SHR-1501 features extended half-life via a unique Fc fusion design and improved stability by cross linking IL-15 with IL-15Rα Sushi domain through a disulfide bond. And another phase I trial of SHR-1501 monotherapy is also ongoing in China.</p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick="pipClose(<i"></a></div></div>  </div></div>		</div>   <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this,2)">				<span class="dis cf">           <h4 class="fleft">SHR-A1811</h4>          <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">HER2 ADC</p>			</a>  <div class="padding20 bgfff miin-height">      <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>            <p class="area_20">II</p>            <p class="area_20">III</p>            <p class="area_20">NDA</p>             <p class="area_20">Launched</p>           </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 214px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative  ">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 191, 45); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>  <div class="mo_dis">     <div class="pipShowlis paddingtop20 positionRelative">          <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> SHR-A1811 is an innovative HER2-targeted antibody-drug conjugate with a bystander payload conjugated to an anti-HER-2 mAb by a cleavable linker. Once bound to HER2 expressing tumor cells, the ADC is internalized and the linker releases the toxin, leading to tumor cell death.
<br>
<br>A global phase I clinical trial for advanced solid tumor is ongoing in China, US, Japan, Australia and the Republic of Korea. A phase I/II clinical trial for advanced NSCLC is ongoing in China</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>			</div>		</div>  <div class="mo_undis">      <div class="area_100 pipShowlis padding10 positionRelative">         <div class="triangle-up"></div>         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>		</div>	</div> <div class="row10 cf pipSeeLis mo_row">  <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this)">				<span class="dis cf">          <h4 class="fleft">SHR1459</h4>           <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">BTK Inhibitor</p>				</a>   <div class="padding20 bgfff miin-height">       <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>              <p class="area_20">II</p>             <p class="area_20">III</p>              <p class="area_20">NDA</p>             <p class="area_20">Launched</p>          </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 107px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative ">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 191, 45); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>   <div class="mo_dis">       <div class="pipShowlis paddingtop20 positionRelative">         <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">Bruton's tyrosine kinase (BTK) is an essential component of the BCR signaling pathway. Inhibition of BTK has been demonstrated to be an effective treatment for B-cell malignancies and autoimmune diseases.
<br>
<br>SHR1459 is a novel, orally available, and covalently-bound BTK inhibitor that exhibits unique pharmacologic properties compared with other BTK inhibitors. SHR1459 is currently under phase I clinical development for Mature B Cell Neoplasms in China. A global phase I clinical trial for B-cell Malignancy is ongoing in Australia and EU.
<br>
<br>In January 2018, TG Therapeutics licensed from Hengrui Pharma worldwide rights, excluding Asia but including Japan, for the development and commercialization of SHR1459 for hematological indications. </p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick="pipClose(<i"></a></div></div>  </div></div>		</div>   <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this,2)">				<span class="dis cf">           <h4 class="fleft">SHR0302</h4>          <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">JAK1 Inhibitor</p>			</a>  <div class="padding20 bgfff miin-height">      <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>            <p class="area_20">II</p>            <p class="area_20">III</p>            <p class="area_20">NDA</p>             <p class="area_20">Launched</p>           </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 214px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative  ">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 191, 45); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 180, 41); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 161, 36); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 214px;">
</div>
</div>
</div></div>     </div>  </div>  <div class="mo_dis">     <div class="pipShowlis paddingtop20 positionRelative">          <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> JAK-STAT signaling pathway involves in the production of multiple inflammatory cytokines in the pathological processes of autoimmune diseases.
<br>
<br>SHR0302 is a clinical-stage JAK1 inhibitor being developed to address multiple diseases.
<br>
<br>SHR0302 is currently in phase III clinical development for the treatment of ulcerative colitis in the US, EU and China. Another phase III clinical trial for atopic dermatitis is being conducted in Canada by Arcutis. Two phase II clinical trials of SHR0302 are ongoing globally for alopecia areata and crohn's disease repectively. Besides, SHR0302 is being studied in phase III and phase II clinical trials for a few more indications in China.
<br>
<br>On Jan 5th 2018, Arcutis obtained the US, EU, and Japan rights for the development of topical SHR0302 for dermatology disorders from Hengrui Pharma. </p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>			</div>		</div>  <div class="mo_undis">      <div class="area_100 pipShowlis padding10 positionRelative">         <div class="triangle-up"></div>         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>		</div>	</div> <div class="row10 cf pipSeeLis mo_row">  <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this)">				<span class="dis cf">          <h4 class="fleft">SHR-1314 (vunakizumab)</h4>           <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">Anti-IL-17 Antibody</p>				</a>   <div class="padding20 bgfff miin-height">       <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>              <p class="area_20">II</p>             <p class="area_20">III</p>              <p class="area_20">NDA</p>             <p class="area_20">Launched</p>          </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 214px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>   <div class="mo_dis">       <div class="pipShowlis paddingtop20 positionRelative">         <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">Interleukin 17 (IL-17) is a pro-inflammatory cytokine, which is associated with numerous immune regulatory functions. IL-17 inhibitors are being investigated as possible treatments for autoimmune disease, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. 
<br>
<br>Vunakizumab, a clinical-stage humanized monoclonal lgG1 antibody, targets both human IL-17A homodimer and IL-17A/F heterodimer to address autoimmune diseases. 
<br>
<br>Four phase I clinical trials in China or Australia and one global phase I/II clinical trial were completed. Two phase I clinical trials, one phase II/III clinical trial, and one phase III clinical trial are ongoing in China. One phase II clinical trial for psoriasis is ongoing in the US and Australia. </p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick="pipClose(<i"></a></div></div>  </div></div>		</div>   <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this,2)">				<span class="dis cf">           <h4 class="fleft">SHR4640</h4>          <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">URAT1 Inhibitor</p>			</a>  <div class="padding20 bgfff miin-height">      <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>            <p class="area_20">II</p>            <p class="area_20">III</p>            <p class="area_20">NDA</p>             <p class="area_20">Launched</p>           </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 214px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative  undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>  <div class="mo_dis">     <div class="pipShowlis paddingtop20 positionRelative">          <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hyperuricemia and gout are metabolic diseases caused by chronic elevation of serum uric acid levels. Uric acids in the renal tubules are re-absorbed into the body by uric acid transporter 1 (URAT1). Inhibition of URAT1 increases urinary excretion of uric acid. 
<br>
<br>SHR4640 is a selective inhibitor of URAT1 being developed as an oral, once-daily treatment for the chronic management of hyperuricemia in patients with gout. 
<br>
<br>SHR4640 is currently in phase III stage in China and a phase I clinical trial is also ongoing in Australia.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>			</div>		</div>  <div class="mo_undis">      <div class="area_100 pipShowlis padding10 positionRelative">         <div class="triangle-up"></div>         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>		</div>	</div> <div class="row10 cf pipSeeLis mo_row">  <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this)">				<span class="dis cf">          <h4 class="fleft">SHR0410</h4>           <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">KOR Agonist</p>				</a>   <div class="padding20 bgfff miin-height">       <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>              <p class="area_20">II</p>             <p class="area_20">III</p>              <p class="area_20">NDA</p>             <p class="area_20">Launched</p>          </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 214px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>   <div class="mo_dis">       <div class="pipShowlis paddingtop20 positionRelative">         <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">The κ-opioid receptor (KOR) is a type of opioid receptor that binds the opioid peptide dynorphin as the primary endogenous ligand. KOR agonists are potently analgesic, and have been employed clinically in the treatment of pain.
<br>
<br>SHR0410 is a novel KOR agonist currently in phase III development for the treatment of pain after endoscopic surgery of the lower abdominal and phase I development for the treatment of pruritus in hemodialysis patients in China. A phase I trial for analgesia and pruritus is ongoing in Australia. </p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick="pipClose(<i"></a></div></div>  </div></div>		</div>   <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this,2)">				<span class="dis cf">           <h4 class="fleft">SHR8008 (VT-1161)</h4>          <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">Fungal CYP51 Inhibitor</p>			</a>  <div class="padding20 bgfff miin-height">      <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>            <p class="area_20">II</p>            <p class="area_20">III</p>            <p class="area_20">NDA</p>             <p class="area_20">Launched</p>           </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(34, 174, 183); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 321px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative  ">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 191, 45); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 180, 41); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 161, 36); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 214px;">
</div>
</div>
</div></div>     </div>  </div>  <div class="mo_dis">     <div class="pipShowlis paddingtop20 positionRelative">          <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> CYP51 is required for the biosynthesis of lanosterol, a key component of the fungal cell membrane. And it has become a favorable drug target for diseases caused by Candida infection such as vulvovaginal Candidiasis (VVC). While there are some effective antifungal agents, they have raised some safety issues due to off-target effects. SHR8008 is designed to be more selective for the fungal enzyme CYP51 than related human CYP enzymes such as CYP3A4, therefore reducing side effects.
<br>
<br>A phase III clinical trial of SHR8008 for VVC and a phase II clinical trial for recurrent vulvovaginal candidiasis (RVVC) are ongoing in China. 
<br>
<br>In June 2019, Hengrui Pharma entered into an exclusive licensing agreement with Mycovia to develop and commercialize VT-1161 for the treatment or prevention of a range of fungal conditions, including RVVC, onychomycosis, and invasive fungal infections. A phase III clinical trial for RVVC run by Mycovia is ongoing in the US, Canada, EU and Japan.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>			</div>		</div>  <div class="mo_undis">      <div class="area_100 pipShowlis padding10 positionRelative">         <div class="triangle-up"></div>         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>		</div>	</div> <div class="row10 cf pipSeeLis mo_row">  <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this)">				<span class="dis cf">          <h4 class="fleft">SHR8028</h4>           <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">CyclASol®, 0.1% cyclosporine A</p>				</a>   <div class="padding20 bgfff miin-height">       <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>              <p class="area_20">II</p>             <p class="area_20">III</p>              <p class="area_20">NDA</p>             <p class="area_20">Launched</p>          </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 214px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative ">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 191, 45); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 180, 41); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 161, 36); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 214px;">
</div>
</div>
</div></div>     </div>  </div>   <div class="mo_dis">       <div class="pipShowlis paddingtop20 positionRelative">         <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">In November 2019, Hengrui Pharma entered into an exclusive licensing agreement with Novaliq GmbH, a Germany-based pharmaceutical company, to develop and commercialize Novaliq's patented investigational products, SHR8028 (CyclASol®, 0.1% cyclosporine A)  and SHR8058 (NOV03, perfluorohexyloctane) for the treatment of ophthalmic diseases including Dry Eye Disease (DED).
<br>
<br>SHR8028 is currently in phase III development for the treatment of DED with an inflammatory disease component in China and the US. </p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick="pipClose(<i"></a></div></div>  </div></div>		</div>   <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this,2)">				<span class="dis cf">           <h4 class="fleft">SHR8058 </h4>          <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">NOV03, perfluorohexyloctane</p>			</a>  <div class="padding20 bgfff miin-height">      <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>            <p class="area_20">II</p>            <p class="area_20">III</p>            <p class="area_20">NDA</p>             <p class="area_20">Launched</p>           </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 214px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative  ">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 191, 45); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 180, 41); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 161, 36); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 214px;">
</div>
</div>
</div></div>     </div>  </div>  <div class="mo_dis">     <div class="pipShowlis paddingtop20 positionRelative">          <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> In November 2019, Hengrui Pharma entered into an exclusive licensing agreement with Novaliq GmbH, a Germany-based pharmaceutical company, to develop and commercialize Novaliq's patented investigational products, SHR8028 (CyclASol®, 0.1% cyclosporine A)  and SHR8058 (NOV03, perfluorohexyloctane) for the treatment of ophthalmic diseases including Dry Eye Disease (DED).
<br>SHR8058 is a semi fluorinated alkane being developed in phase III for the treatment of DED associated with Meibomian gland dysfunction (MGD) in China and the US.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>			</div>		</div>  <div class="mo_undis">      <div class="area_100 pipShowlis padding10 positionRelative">         <div class="triangle-up"></div>         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>		</div>	</div> <div class="row10 cf pipSeeLis mo_row">  <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this)">				<span class="dis cf">          <h4 class="fleft">SHR-1707</h4>           <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">Anti-Aβ Antibody</p>				</a>   <div class="padding20 bgfff miin-height">       <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>              <p class="area_20">II</p>             <p class="area_20">III</p>              <p class="area_20">NDA</p>             <p class="area_20">Launched</p>          </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative ">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 191, 45); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>   <div class="mo_dis">       <div class="pipShowlis paddingtop20 positionRelative">         <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">Accumulation of amyloid-β (Aβ) peptide has been recognized as a core pathology in Alzheimer’s Disease (AD). The imbalance between production and clearance of Aβ can be a very early, often initiating factor of AD. Thus, anti-Aβ therapeutic approaches have been extensively studied in the past few decades as disease-modifying treatments for AD
<br>
<br>SHR-1707 is a novel anti-Aβ monoclonal antibody currently under phase I development in Australia.</p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick="pipClose(<i"></a></div></div>  </div></div>		</div>   <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this,2)">				<span class="dis cf">           <h4 class="fleft">Mecapegfilgrastim</h4>          <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">Long-Acting PEG-rhG-CSF </p>			</a>  <div class="padding20 bgfff miin-height">      <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>            <p class="area_20">II</p>            <p class="area_20">III</p>            <p class="area_20">NDA</p>             <p class="area_20">Launched</p>           </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(34, 174, 183); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(37, 166, 195); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 428px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative  undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>  <div class="mo_dis">     <div class="pipShowlis paddingtop20 positionRelative">          <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Neutropenia is a common adverse effect for as many as one in three patients receiving chemotherapy. Granulocyte-colony stimulating factor (G-CSF) stimulates the production of granulocytes, including neutrophils. In oncology and hematology, a recombinant form of G-CSF is used to accelerate recovery and reduce mortality from neutropenia associated with chemotherapy, allowing higher adherence to the prescribed chemotherapy regimens.
<br>
<br>Mecapegfilgrastim is a novel PEGylated human recombinant G-CSF that enables once per chemotherapy cycle injection, rather than daily injection. A total of five completed/ongoing clinical trials (including one Ia trial in healthy volunteers) among NSCLC and breast cancer patients have fully validated mecapegfilgrastim’s superior ability to reduce neutropenia.
<br>
<br>Mecapegfilgrastim received marketing approval in China in July 2018. </p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>			</div>		</div>  <div class="mo_undis">      <div class="area_100 pipShowlis padding10 positionRelative">         <div class="triangle-up"></div>         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>		</div>	</div> <div class="row10 cf pipSeeLis mo_row">  <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this)">				<span class="dis cf">          <h4 class="fleft">Apatinib</h4>           <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">VEGFR2 inhibitor</p>				</a>   <div class="padding20 bgfff miin-height">       <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>              <p class="area_20">II</p>             <p class="area_20">III</p>              <p class="area_20">NDA</p>             <p class="area_20">Launched</p>          </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(34, 174, 183); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(37, 166, 195); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 428px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>   <div class="mo_dis">       <div class="pipShowlis paddingtop20 positionRelative">         <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">Vascular endothelial growth factor receptors (VEGFR) are a family of receptor tyrosine kinases, which play an important role in both vasculogenesis and angiogenesis. Among all subtypes, sVEGFR inhibitors were approved for oncology treatment, and more molecules are under development. 
<br>
<br>Apatinib is a selective VEGFR-2 inhibitor which also mildly inhibits c-Kit and c-Src tyrosine kinases. It is the first approved small-molecule targeted therapy for late-stage gastric cancer in the world, with good efficacy and safety profiles demonstrated in both pre- and post-marketing studies.
<br>
<br>Apatinib is marketed in China in 2014. A global phase III clinical study of camrelizumab (anti-PD-1 antibody) plus apatinib vs. sorafenib as the first-line therapy for advanced hepatocellular carcinoma (HCC) is ongoing.</p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick="pipClose(<i"></a></div></div>  </div></div>		</div>   <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this,2)">				<span class="dis cf">           <h4 class="fleft">HRS-3536 (Linperlisib)</h4>          <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">PI3Kδ Inhibitor</p>			</a>  <div class="padding20 bgfff miin-height">      <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>            <p class="area_20">II</p>            <p class="area_20">III</p>            <p class="area_20">NDA</p>             <p class="area_20">Launched</p>           </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(34, 174, 183); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 321px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative  undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>  <div class="mo_dis">     <div class="pipShowlis paddingtop20 positionRelative">          <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling is one of the most important intracellular pathways, which regulates cell growth, motility, survival, metabolism, and angiogenesis. Hyperactivation of PI3K/AKT pathway contributes to various human cancers.
<br>
<br>HRS-3536 is an orally available inhibitor selectively targets PI3K subunit delta to prevent the activation of the PI3K/AKT signaling pathway. Such targeted inhibition induces cell death in PI3Kδ over-expressing cells while preserving PI3K signaling in non-neoplastic cells, thereby minimizing serious side effects. HRS-3536 is currently under NDA review in China. FDA granted Orphan Drug Designation to HRS-3536 to treat follicular lymphoma (FL) and chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). NMPA granted Breakthrough Therapy Designation to HRS-3536 to treat r/r FL.
<br>
<br>In February 2021, Hengrui Pharma entered into a strategic agreement with Yingli Pharma. Hengrui Pharma obtained joint development rights and exclusive rights for commercializing HRS-3536 in China. </p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>			</div>		</div>  <div class="mo_undis">      <div class="area_100 pipShowlis padding10 positionRelative">         <div class="triangle-up"></div>         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>		</div>	</div> <div class="row10 cf pipSeeLis mo_row">  <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this)">				<span class="dis cf">          <h4 class="fleft">SHR2554</h4>           <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">EZH2 inhibitor </p>				</a>   <div class="padding20 bgfff miin-height">       <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>              <p class="area_20">II</p>             <p class="area_20">III</p>              <p class="area_20">NDA</p>             <p class="area_20">Launched</p>          </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>   <div class="mo_dis">       <div class="pipShowlis paddingtop20 positionRelative">         <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">Enhancer of zeste homologue 2 (EZH2) is an enzymatic subunit of polycomb repressive complex 2 (PRC2), which silences tumor suppressor genes in cancer cells. Selective inhibition of histone methyltransferase EZH2 downregulates the methylation of H3K27, reducing tumor cell proliferation. 
<br>
<br>SHR2554 inhibits the wild-type and mutated histone methyltransferase EZH2, preventing the methylation of H3K27. As a result, it alters gene expression patterns associated with cancer pathways and decreases tumor cell proliferation in EZH2 mutated cancer cells. SHR2554 is currently under phase I clinical development for relapsed or refractory mature lymphoid neoplasms.</p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick="pipClose(<i"></a></div></div>  </div></div>		</div>   <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this,2)">				<span class="dis cf">           <h4 class="fleft">Anti-TIM-3 Antibody</h4>          <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10"></p>			</a>  <div class="padding20 bgfff miin-height">      <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>            <p class="area_20">II</p>            <p class="area_20">III</p>            <p class="area_20">NDA</p>             <p class="area_20">Launched</p>           </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative  undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>  <div class="mo_dis">     <div class="pipShowlis paddingtop20 positionRelative">          <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) functions as a T-cell inhibitory receptor to limit the duration and magnitude of Th1 and Tc1 T-cell response. The blockage of TIM-3 knocks out the immune suppression in tumor tissues, restoring function of disabled CD8+ T cells. Anti-TIM-3 antibody has also showed a potential synergy with anti-PD-1 antibody.
<br>
<br>A novel anti-TIM-3 antibody is under development by Hengrui for the treatment of solid tumors and hematological malignancies. A phase I clinical trial of the antibody as monotherapy in relapsed/refractory AML and intermediate-high risk MDS is ongoing.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>			</div>		</div>  <div class="mo_undis">      <div class="area_100 pipShowlis padding10 positionRelative">         <div class="triangle-up"></div>         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>		</div>	</div> <div class="row10 cf pipSeeLis mo_row">  <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this)">				<span class="dis cf">          <h4 class="fleft">SHR-1802</h4>           <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">Anti-LAG-3 Antibody</p>				</a>   <div class="padding20 bgfff miin-height">       <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>              <p class="area_20">II</p>             <p class="area_20">III</p>              <p class="area_20">NDA</p>             <p class="area_20">Launched</p>          </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 107px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>   <div class="mo_dis">       <div class="pipShowlis paddingtop20 positionRelative">         <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint receptor protein found on the cell surface of effector T cells and regulatory T cells (Tregs) and functions to control T cell response, activation and growth. In cancer, LAG-3 expressing exhausted cytotoxic T cells and Tregs expressing LAG-3 gather at tumor sites. Inhibition of LAG-3 could potentially restore the active antitumor activity of T cells.
<br>
<br>SHR-1802 is a mAb specific for LAG-3 and is currently under phase I clinical development stage for malignant tumors.</p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick="pipClose(<i"></a></div></div>  </div></div>		</div>   <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this,2)">				<span class="dis cf">           <h4 class="fleft">PEG-IL-2</h4>          <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10"></p>			</a>  <div class="padding20 bgfff miin-height">      <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>            <p class="area_20">II</p>            <p class="area_20">III</p>            <p class="area_20">NDA</p>             <p class="area_20">Launched</p>           </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative  undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>  <div class="mo_dis">     <div class="pipShowlis paddingtop20 positionRelative">          <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Interleukin-2 (IL-2) is a cytokine that plays an important role in the preservation of T cell homeostasis and proper immune regulation. It has been studied for a long time as an immunotherapy and has shown great efficacy in treating several cancers. Hengrui has developed a novel polyethylene glycol conjugated human recombinant cytokine IL-2 that induces antineoplastic activity.  
<br>
<br>The drug candidate is currently under phase I clinical development stage for solid tumors.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>			</div>		</div>  <div class="mo_undis">      <div class="area_100 pipShowlis padding10 positionRelative">         <div class="triangle-up"></div>         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>		</div>	</div> <div class="row10 cf pipSeeLis mo_row">  <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this)">				<span class="dis cf">          <h4 class="fleft">Retagliptin</h4>           <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">DPP-4 Inhibitor</p>				</a>   <div class="padding20 bgfff miin-height">       <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>              <p class="area_20">II</p>             <p class="area_20">III</p>              <p class="area_20">NDA</p>             <p class="area_20">Launched</p>          </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(34, 174, 183); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 321px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>   <div class="mo_dis">       <div class="pipShowlis paddingtop20 positionRelative">         <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">GLP-1 and GIP are incretins that regulate blood glucose levels by increasing insulin release and decreasing glucagon secretion. Dipeptidyl peptidase 4 (DPP-4) is an enzyme that degrades GLP-1 and GIP. The inhibition of DPP-4 preserves the functions of GLP-1 and GIP to control the blood glucose level. 
<br>
<br>Retagliptin is an NDA-stage DPP-4 inhibitor for the treatment of type 2 diabetes. In completed phase II trials, retagliptin monotherapy or in combination with metformin significantly decreased the HbA1c level in type 2 diabetic patients. </p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick="pipClose(<i"></a></div></div>  </div></div>		</div>   <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this,2)">				<span class="dis cf">           <h4 class="fleft">SHR20004</h4>          <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">GLP-1 Receptor Agonist</p>			</a>  <div class="padding20 bgfff miin-height">      <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>            <p class="area_20">II</p>            <p class="area_20">III</p>            <p class="area_20">NDA</p>             <p class="area_20">Launched</p>           </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 107px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative  undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>  <div class="mo_dis">     <div class="pipShowlis paddingtop20 positionRelative">          <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Glucagon-like peptide-1 (GLP-1) is one of incretins that increases insulin secretion and inhibits glucagon release when glucose levels are elevated. GLP-1 is an important target for metabolic disease. type 2 diabetes since it has the potential of decreasing plasma glucose levels with low risk of hypoglycemia. 
<br>
<br>SHR20004 is a phase II-stage subcutaneous injectable GLP-1 receptor agonist for metabolic diseases. </p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>			</div>		</div>  <div class="mo_undis">      <div class="area_100 pipShowlis padding10 positionRelative">         <div class="triangle-up"></div>         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>		</div>	</div> <div class="row10 cf pipSeeLis mo_row">  <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this)">				<span class="dis cf">          <h4 class="fleft">SHR-1209</h4>           <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">Anti-PCSK9 Antibody</p>				</a>   <div class="padding20 bgfff miin-height">       <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>              <p class="area_20">II</p>             <p class="area_20">III</p>              <p class="area_20">NDA</p>             <p class="area_20">Launched</p>          </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 214px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>   <div class="mo_dis">       <div class="pipShowlis paddingtop20 positionRelative">         <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">Proprotein convertase subtilin/kexin type 9 (PCSK9) binds to low-density lipoprotein receptors (LDLR), enhancing the lysosomal degradation of LDLR. The blockage of PCSK9 increases LDLR recycling; therefore, more LDLRs are present on the cell membranes to uptake LDL into cells. As a result, PCSK9 blockage decreases blood LDL concentrations.
<br>
<br>SHR-1209 is a PCSK9 inhibitor being developed for hypercholesterolemia. SHR-1209 is currently under phase III development in China.</p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick="pipClose(<i"></a></div></div>  </div></div>		</div>   <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this,2)">				<span class="dis cf">           <h4 class="fleft">SHR3824  (henagliflozin)</h4>          <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">SGLT2 Inhibitor</p>			</a>  <div class="padding20 bgfff miin-height">      <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>            <p class="area_20">II</p>            <p class="area_20">III</p>            <p class="area_20">NDA</p>             <p class="area_20">Launched</p>           </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(34, 174, 183); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(37, 166, 195); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 428px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative  undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>  <div class="mo_dis">     <div class="pipShowlis paddingtop20 positionRelative">          <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Sodium-glucose transport protein 2 (SGLT2) is the major co-transporter responsible for 90% of glucose reabsorption in the kidney. The inhibition of SGLT2 decreases blood glucose levels by reducing urine glucose reabsorption and increasing glucose excretion. 
<br>
<br>SHR3824 is an approved SGLT2 inhibitor for the treatment of type 2 diabetes. In completed phase II trials, SHR3824 monotherapy or in combination with metformin effectively decreased the HbA1c, FPG, 2h PPG, body weight, and blood pressure in type 2 diabetes patients. 
<br>
<br>Two phase III trials for SHR3824 monotherapy and in combination with metformin were completed in China. </p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>			</div>		</div>  <div class="mo_undis">      <div class="area_100 pipShowlis padding10 positionRelative">         <div class="triangle-up"></div>         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>		</div>	</div> <div class="row10 cf pipSeeLis mo_row">  <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this)">				<span class="dis cf">          <h4 class="fleft">INS068</h4>           <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">Long-Acting Basal Insulin</p>				</a>   <div class="padding20 bgfff miin-height">       <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>              <p class="area_20">II</p>             <p class="area_20">III</p>              <p class="area_20">NDA</p>             <p class="area_20">Launched</p>          </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 107px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative ">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 191, 45); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 180, 41); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 107px;">
</div>
</div>
</div></div>     </div>  </div>   <div class="mo_dis">       <div class="pipShowlis paddingtop20 positionRelative">         <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">In patients with diabetes, the destruction or dysfunction of beta cells of pancreatic islets results in less secretion of insulin, and thus leads to high blood glucose levels. Administration of basal insulin helps diabetic patients to maintain a needed level of insulin and to keep their blood glucose in stable levels during fasting period. 
<br>
<br>INS068 is a long-acting basal insulin currently under phase II clinical development for Type 2 Diabetes in China, US and Australia.</p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick="pipClose(<i"></a></div></div>  </div></div>		</div>   <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this,2)">				<span class="dis cf">           <h4 class="fleft">SHR7280</h4>          <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10"> GnRH Antagonist</p>			</a>  <div class="padding20 bgfff miin-height">      <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>            <p class="area_20">II</p>            <p class="area_20">III</p>            <p class="area_20">NDA</p>             <p class="area_20">Launched</p>           </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 214px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative  undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>  <div class="mo_dis">     <div class="pipShowlis paddingtop20 positionRelative">          <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Endometriosis is an estrogen-dependent disease that is treatable by estrogen withdrawal. Gonadotropin-releasing hormone antagonists (GnRH antagonists) could bind to GnRH receptor, and thus inhibit the synthesis and release of gonadotropins, and therefore decrease the levels of estrogens and androgens. GnRH antagonists have been developed to treat endometriosis and fibroids. 
<br>
<br>SHR7280 is an oral GnRH antagonist that competitively binds to GnRH receptor. A phase I/II clinical trial for the treatment of endometriosis is ongoing in China.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>			</div>		</div>  <div class="mo_undis">      <div class="area_100 pipShowlis padding10 positionRelative">         <div class="triangle-up"></div>         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>		</div>	</div> <div class="row10 cf pipSeeLis mo_row">  <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this)">				<span class="dis cf">          <h4 class="fleft">Factor XI (FXI) Antagonist</h4>           <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10"></p>				</a>   <div class="padding20 bgfff miin-height">       <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>              <p class="area_20">II</p>             <p class="area_20">III</p>              <p class="area_20">NDA</p>             <p class="area_20">Launched</p>          </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative ">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 191, 45); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>   <div class="mo_dis">       <div class="pipShowlis paddingtop20 positionRelative">         <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">FXI is a central player in thrombin generation in the amplification phase and may lead to overexpression of thrombin with excessive clots formation resulting in pathologic thrombosis. It has become a favorable antithrombotic drug target because selective inhibition of FXI would leave the extrinsic and common pathways of coagulation intact and therefore have less impact on hemostasis.
<br>
<br>A novel FXI antagonist developed by Hengrui is currently at phase I clinical stage. </p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick="pipClose(<i"></a></div></div>  </div></div>		</div>   <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this,2)">				<span class="dis cf">           <h4 class="fleft">Hetrombopag</h4>          <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10"> Thrombopoietin Receptor Agonist </p>			</a>  <div class="padding20 bgfff miin-height">      <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>            <p class="area_20">II</p>            <p class="area_20">III</p>            <p class="area_20">NDA</p>             <p class="area_20">Launched</p>           </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(34, 174, 183); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(37, 166, 195); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 428px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative  ">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(255, 191, 45); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>  <div class="mo_dis">     <div class="pipShowlis paddingtop20 positionRelative">          <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Thrombopotetin regulates the production of platelets by activation of the thrombopoietin receptor (TPOR). TPOR agonists are novel treatments for thrombocytopenia.
<br>
<br>Hetrombopag is a TPO receptor agonist approved in China in 2021 for idiopathic thrombocytopenic purpura (ITP) and second line severe aplastic anemia (SAA).The indications of chemotherapy-induced thrombocytopenia (CIT), pediatric/juvenile ITP and naïve severe aplastic anemia are under development. A phase I trial is ongoing in Australia.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>			</div>		</div>  <div class="mo_undis">      <div class="area_100 pipShowlis padding10 positionRelative">         <div class="triangle-up"></div>         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>		</div>	</div> <div class="row10 cf pipSeeLis mo_row">  <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this)">				<span class="dis cf">          <h4 class="fleft">SHR-1703</h4>           <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10"> Anti-IL-5 Antibody</p>				</a>   <div class="padding20 bgfff miin-height">       <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>              <p class="area_20">II</p>             <p class="area_20">III</p>              <p class="area_20">NDA</p>             <p class="area_20">Launched</p>          </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>   <div class="mo_dis">       <div class="pipShowlis paddingtop20 positionRelative">         <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">Interleukin-5 (IL-5) exerts a central pathogenic role in differentiation, recruitment, survival, and degranulation of eosinophils. Many patients with severe asthma express a type 2 (T2)-high phenotype featured by eosinophilic inflammation. Biologic agents targeting IL-5 have shown effects in reducing the rate of asthma exacerbations
<br>
<br>SHR-1703 is a mAb of IL-5 currently under phase I development stage in China and Australia.</p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick="pipClose(<i"></a></div></div>  </div></div>		</div>   <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this,2)">				<span class="dis cf">           <h4 class="fleft">Imrecoxib</h4>          <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">COX-2 Inhibitor</p>			</a>  <div class="padding20 bgfff miin-height">      <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>            <p class="area_20">II</p>            <p class="area_20">III</p>            <p class="area_20">NDA</p>             <p class="area_20">Launched</p>           </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(34, 174, 183); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(37, 166, 195); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 428px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative  undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>  <div class="mo_dis">     <div class="pipShowlis paddingtop20 positionRelative">          <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Cyclooxygenase (COX) is an enzyme that is responsible for production of prostanoids, including thromboxane and prostaglandins (PGs). PGs promote inflammation, pain, and fever. Selective COX-2 inhibitor is a subclass of NSAIDs, which inhibits the formation of PGs to reduce inflammation, pain, and fever. 
<br>
<br>Imrecoxib is a highly selective COX-2 inhibitor approved in China in 2011, which relieves the pain induced by osteoarthritis.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>			</div>		</div>  <div class="mo_undis">      <div class="area_100 pipShowlis padding10 positionRelative">         <div class="triangle-up"></div>         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>		</div>	</div> <div class="row10 cf pipSeeLis mo_row">  <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this)">				<span class="dis cf">          <h4 class="fleft">Remimazolam</h4>           <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">Short-Lasting GABAα Receptor Agonist </p>				</a>   <div class="padding20 bgfff miin-height">       <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>              <p class="area_20">II</p>             <p class="area_20">III</p>              <p class="area_20">NDA</p>             <p class="area_20">Launched</p>          </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(34, 174, 183); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(37, 166, 195); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 428px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>   <div class="mo_dis">       <div class="pipShowlis paddingtop20 positionRelative">         <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">Gamma-aminobutyric acid (GABA) is an important inhibitory neurotransmitter in mammalian central nervous system. Activation of GABA receptors results in neural inhibition, reducing neuronal excitability, sedation, and amnesia etc. 
<br>
<br>Remimazolam is a short-lasting GABAα receptor agonist for anesthesia and conscious sedation for minor invasive procedures. Remimazolam is currently approved in China for the treatment of gastroscopy sedation and colonoscopy sedation. NDA was filed for the indication of general anesthesia and phase III clinical trial for the treatment of fibrobronchoscope sedation is ongoing.  </p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick="pipClose(<i"></a></div></div>  </div></div>		</div>   <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this,2)">				<span class="dis cf">           <h4 class="fleft">SHR8554</h4>          <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">MOR Agonist</p>			</a>  <div class="padding20 bgfff miin-height">      <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>            <p class="area_20">II</p>            <p class="area_20">III</p>            <p class="area_20">NDA</p>             <p class="area_20">Launched</p>           </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(26, 198, 147); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(30, 186, 165); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 214px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative  undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>  <div class="mo_dis">     <div class="pipShowlis paddingtop20 positionRelative">          <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Opioid analgesics have been used for a long time in the treatment of pain and related disorders. The μ-opioid receptors (MOR) are a class of opioid receptors with a high affinity for enkephalins and beta-endorphin, but a low affinity for dynorphins. MOR can mediate acute changes in neuronal excitability via suppression of presynaptic release of GABA. 
<br>
<br>SHR8554 is a selective biased μ-opioid receptor agonist which activates the 
<br>MOR-mediated G-protein coupling, but barely recruits β-arrestin-2. It has demonstrated remarkable analgesic effects in a variety of acute pains with significant improvement in DI dysfunction. Two phase IIb/III trials for acute postoperative pain are ongoing in China.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>			</div>		</div>  <div class="mo_undis">      <div class="area_100 pipShowlis padding10 positionRelative">         <div class="triangle-up"></div>         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>		</div>	</div> <div class="row10 cf pipSeeLis mo_row">  <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this)">				<span class="dis cf">          <h4 class="fleft">HRS9950</h4>           <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">TLR8 Inhibitor</p>				</a>   <div class="padding20 bgfff miin-height">       <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>              <p class="area_20">II</p>             <p class="area_20">III</p>              <p class="area_20">NDA</p>             <p class="area_20">Launched</p>          </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>   <div class="mo_dis">       <div class="pipShowlis paddingtop20 positionRelative">         <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">Toll-like receptor 8 (TLR8) is mainly expressed on the endosome of cells, which can recognize the single-stranded RNA of virus or bacterial and some small molecule ligands. In liver tissues infected by HBV, TLR8 agonists can induce IL-12 and IFN-γ cytokines through NF-κB and IRF signaling pathways, exerting direct antiviral effects. TLR8 agonists can also indirectly activate adaptive immunity, by increasing the antigen presentation function of DC cells, promoting the differentiation and maturation process of liver lymphatic B cells and T cells, further killing viruses that infect liver cells.
<br>
<br>HRS9950 is a novel small molecule selectively targeting TLR8, with potential to stimulate adaptive immune responses and cure chronic hepatitis B (CHB). One phase I multi-center basket trial is ongoing, and more trials are under planning. </p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick="pipClose(<i"></a></div></div>  </div></div>		</div>   <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this,2)">				<span class="dis cf">           <h4 class="fleft">HRS5091</h4>          <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">HBV Core Protein Inhibitor </p>			</a>  <div class="padding20 bgfff miin-height">      <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>            <p class="area_20">II</p>            <p class="area_20">III</p>            <p class="area_20">NDA</p>             <p class="area_20">Launched</p>           </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative  undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>  <div class="mo_dis">     <div class="pipShowlis paddingtop20 positionRelative">          <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hepatitis B virus (HBV) core protein (HBc) plays important roles in viral life cycle, especially in capsid assembly. HRS5091 is an oral, class II, selective HBV capsid inhibitor with pan-genotypic activity. It interferes the uncoating process of nucleocapsid, which inhibits the formation of covalently closed circular DNA (cccDNA).
<br>
<br>A phase I clinical trial is ongoing in China, and more trials are under planning.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>			</div>		</div>  <div class="mo_undis">      <div class="area_100 pipShowlis padding10 positionRelative">         <div class="triangle-up"></div>         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>		</div>	</div> <div class="row10 cf pipSeeLis mo_row">  <div class="area_50 padding10 pipSeeChile">       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick="showlis(this)">				<span class="dis cf">          <h4 class="fleft">SHR-1222</h4>           <i class="fright iconfont icon-jt fa-1_6x"></i>      </span>      <p class="fontSize12 paddingtop10">Anti-SOST Antibody</p>				</a>   <div class="padding20 bgfff miin-height">       <div class="cf">          <div class="cadeProcess marginauto">              <p class="area_20">I</p>              <p class="area_20">II</p>             <p class="area_20">III</p>              <p class="area_20">NDA</p>             <p class="area_20">Launched</p>          </div>      </div>       <div class="pipStep cf positionRelative  ">           <p class="area_10 poabsolute-h50">China</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(23, 207, 134); color: rgb(255, 255, 255);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:424px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>      </div>      <div class="globalStep cf positionRelative undis">         <p class="area_10 poabsolute-h50">Global</p>          <div class="perSteps width90 fright"><div class="bar-content">
<ul class="cf bar-circle-ul">
<li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li><li class="" style=" width:20%"><div class="cf li-div" style="background: rgb(221, 221, 221); color: rgb(37, 37, 37);"><span class="li-span" style="color: rgb(0, 0, 0);"></span></div></li></ul>
</div>

<div class="bar-box" style=" width:0px">
<div class="bar-bg">
<div class="bar-color" style="width: 0px;">
</div>
</div>
</div></div>     </div>  </div>   <div class="mo_dis">       <div class="pipShowlis paddingtop20 positionRelative">         <div class="triangle-up"></div>          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">Sclerostin is a glycoprotein inhibitor of osteoblast Wnt signaling produced by osteocytes. Research studies found that mutations of the sclerostin gene SOST are associated with high bone mass, which suggested that inhibitors of sclerostin might be used to increase bone mineral density and could therefore be developed as therapeutic intervention in patients with osteoporosis.  
<br>
<br>SHR-1222 is a novel SOST monoclonal antibody currently under phase I development.</p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick="pipClose(<i"></a></div></div>  </div></div>		</div>  <div class="mo_undis">      <div class="area_100 pipShowlis padding10 positionRelative">         <div class="triangle-up"></div>         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick="pipClose(<i"></a></div></div>  </div>		</div>	</div></div>
					<div id="tab2" style="display: none;"></div>
					<div id="tab3" style="display: none;"></div>
					<div id="tab4" style="display: none;"></div>
					<div id="tab5" style="display: none;"></div>
					<div id="tab6" style="display: none;"></div>
                    <div id="tab7" style="display: none;"></div>
				</div>
			</section>
			<section class="footbox"><div class="paddingtop50 paddingbottom50 mo_paddingtop30 mo_paddingbottom30 bg04357c colorfff">

    <div class="container cf fontSize12 mo_undis">
        <p class="tcenter area_70"><span class="padding5">©</span>2021 Jiangsu Hengrui Pharmaceuticals Co., Ltd.  All rights reserved <a href="https://beian.miit.gov.cn/#/Integrated/index" target="_blank">苏ICP备11027260号-13</a>互联网资格证书:(苏)-非经营性-2018-0018</p>
        <a target="_blank" href="http://www.beian.gov.cn/portal/registerSystemInfo?recordcode=32070402010095" style="display:inline-block;text-decoration:none;height:20px;line-height:20px;" class="area_30"><img src="/en/images/records.png" style="float:left;"><p style="float:left;height:20px;line-height:20px;margin: 0px 0px 0px 5px;">苏公网安备 32070402010095号</p></a>
    </div>
    <div class="container cf fontSize12 mo_dis">
        <p><span class="padding5">©</span>2021 Jiangsu Hengrui Pharmaceuticals Co., Ltd.  All rights reserved </p>
        <p><a href="https://beian.miit.gov.cn/#/Integrated/index" target="_blank">苏ICP备11027260号-13</a>互联网资格证书:(苏)-非经营性-2018-0018</p>
        <div class="tcenter"><a target="_blank" href="http://www.beian.gov.cn/portal/registerSystemInfo?recordcode=32070402010095" class="disinblock paddingtop10"><img src="/en/images/records.png" class="fleft"><p class="fleft">苏公网安备 32070402010095号</p></a></div>
    </div>
</div>

<a class="gototop" id="gototop" href="javascript:void(0);" onclick="goTop();return false;">
	<i class="iconfont icon-up"></i>
</a>

 
	    
 
 </section>
			
		</article>
		
		<script src="/en/js/step.js"></script>
		<script src="/en/js/aos.js"></script>
		
		<script> 

            function resetTabs() {
                $("#content > div").hide(); //Hide all content
                $("#tabs a").attr("id", ""); //Reset id's      
            }

            (function () {
                $("#content > div").hide(); // Initially hide all content
                $("#tabs :first a").attr("id", "current"); // Activate first tab
                $("#content > div:first").fadeIn(); // Show first tab content
                $("#tabs a").on("click", function (e) {
                    e.preventDefault();
                    if ($(this).attr("id") == "current") { //detection for current tab
                        return
                    }
                    else {
                        resetTabs();
                        $(this).attr("id", "current"); // Activate this
						$($(this).attr('name')).fadeIn(); // Show content for current tab

						var type=parseInt($("#current").attr("value"))-1
                        if (type>0)
						{
                            _Ajax("", {
                                "action": "select",
                                "type": type
							}, function (x) {
									if (x.data.length > 0)
									{
										binddata(x.data, $("#current").attr("name"));

									}
                                    

                            })

						}
                        
					}

                });
            })();


           
           	if ($(window).width() > 800){
			function showlis(i,num){
			var jtIcon = $(i).find('.icon-jt');
			var pipSeeLis=$(i).closest('.pipSeeLis');
			var pipShowlis=pipSeeLis.find('.pipShowlis');
			if($(jtIcon).attr('class')=="fright iconfont icon-jt fa-1_6x"){
				pipSeeLis.find(".icon-jt").removeClass('transform_180');
				$(jtIcon).addClass("transform_180");
				$(i).closest('.pipSeeLis').find('.mo_undis').find('.zindex2').html($(i).closest('.pipSeeChile').find('.zindex2').html());
			    $(pipShowlis).fadeIn(300); 
				if(num==2){
					$(pipShowlis).find('.triangle-up').addClass('rightSet')
				 }else{
					$(pipShowlis).find('.triangle-up').removeClass('rightSet') 
				 }
			}else{
				$(i).closest(".pipSeeLis").find(".icon-jt").removeClass('transform_180');
				//$('.icon-jt').removeClass('transform_180');
				$(pipShowlis).find('.triangle-up').removeClass('rightSet') 
				pipSeeLis.find(".pipShowlis").fadeOut(300);
			}
		}	
		function pipClose(ii){
			var jtIcon = $(ii).closest('.pipSeeLis').find('.icon-jt');
			$(ii).closest('.pipSeeLis').find('.pipShowlis').fadeOut(300)
			$(jtIcon).removeClass('transform_180');
		} 

            } else {
			function showlis(i){
				var jtIcon = $(i).find('.icon-jt')
				if($(jtIcon).attr('class')=="fright iconfont icon-jt fa-1_6x"){
				$(jtIcon).addClass("transform_180");
				$(i).closest('.pipSeeChile').find('.pipShowlis').fadeIn(300)
			}else{
				$(jtIcon).removeClass('transform_180');
				 $(i).closest('.pipSeeChile').find('.pipShowlis').fadeOut(300)
			 }
			}
			function pipClose(ii){
			var jtIcon = $(ii).closest('.pipSeeChile').find('.icon-jt');
			$(ii).closest('.pipSeeChile').find('.pipShowlis').fadeOut(300)
			$(jtIcon).removeClass('transform_180');
		} 
            }
			$(function () {

				
				var data =[
  {
    "id": 2,
    "type": 1,
    "title": "SHR-1210 (camrelizumab)",
    "subtitle": "Anti-PD-1 Antibody",
    "chinalevel": 5,
    "globallevel": 3,
    "remarks": "Programmed cell death protein (PD-1) is an immune checkpoint that guards against autoimmunity and prevents the immune system from killing cancer cells. Anti-PD-1 antibody blocks the interaction between PD-1 and PD-L1, activating the immune system to kill cancer cells. In recent years, PD-1/PD-L1 antibodies have become the backbone of immune oncology therapies. \r\n\r\nCamrelizumab is an anti-PD-1 mAb approved in China in 2019. Camrelizumab is approved for the treatment of 1L NSCLC, 2L HCC, 2L EC, 3L r/r cHL, ≥ 2L NPC, and 1L NPC in China. Another 8 NDAs were submitted. According to Evaluate Pharma, camrelizumab is projected to be the 3rd best selling anti-PD-1 antibody worldwide, only after Keytruda and Opdivo. The user experience is highly positive in China.\r\n\r\nA total of 34 trials for camrelizumab are ongoing/completed. A global phase III clinical study of camrelizumab plus apatinib (VEGFR2 inhibitor) vs. sorafenib as the first-line therapy in patients with advanced hepatocellular carcinoma (HCC) is ongoing. FDA granted Orphan Drug Designation to camrelizumab for HCC. First BLA submission in the US/EU (1L HCC) is expected in Q4 2021.\r\n\r\nIn April 2020, Hengrui Pharma licensed the Korean rights of camrelizumab to CrystalGenomics Inc., a biotech company based in the Republic of Korea.",
    "idx": 10000,
    "isdelete": 0,
    "addtime": "2021-06-25T15:24:48.71",
    "vid": 1
  },
  {
    "id": 1,
    "type": 1,
    "title": "SHR-1258 (pyrotinib)",
    "subtitle": "EGFR/HER2/HER4 TKI ",
    "chinalevel": 5,
    "globallevel": 3,
    "remarks": "Pyrotinib selectively and irreversibly inhibits the phosphorylation and downstream signaling of EGFR/HER2/HER4 tyrosine kinases. Pyrotinib received the marketing approval in China for the 2L treatment of relapsed or metastatic HER2-positive breast cancer in combination with capecitabine in July 2020. \r\n\r\nA total of 21 clinical trials for pyrotinib are completed or ongoing, including 6 phase III trials for neoadjuvant, extended adjuvant, 1st line, and 2nd line treatment for HER2+ breast cancer in China, as well as a global phase III trial for HER2 mutant NSCLC (ongoing in ≥6 countries/regions).\r\n\r\nIn September 2020, Hengrui Pharma licensed the Korean rights of pyrotinib to HLB Life Science Co., Ltd., a biotech company based in the Republic of Korea.",
    "idx": 9990,
    "isdelete": 0,
    "addtime": "2021-06-25T15:09:16.16",
    "vid": 1
  },
  {
    "id": 5,
    "type": 1,
    "title": "SHR3162 (fuzuloparib)",
    "subtitle": "PARP Inhibitor",
    "chinalevel": 5,
    "globallevel": 3,
    "remarks": "Poly ADP ribose polymerase (PARP) is an enzyme that detects and initiates an immediate cellular response to metabolic, chemical, or radiation-induced single-strand DNA breaks. In BRCA1/2 mutated cancer cells, where the double-strand DNA break repairing function was damaged, the inhibition of PARP induces death of cancer cells but not normal cells. \r\n\r\nFuzuloparib received the marketing approval in China for the treatment of BRCA-mutated recurrent ovarian cancer in Dec 2020 and the maintenance treatment of recurrent ovarian cancer in June 2021. \r\n\r\nThirteen clinical trials for fuzuloparib have been completed, additional fourteen trials are ongoing including five phase III trials for ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer, and two phase Ib trials for TNBC and SCLC.  \r\n\r\nA global phase III trial is ongoing to study the combination of SHR3162, abiraterone and prednisone vs. abiraterone and prednisone for the 1L treatment of mCRPC in the US, EU, Australia and the Republic of Korea. ",
    "idx": 9970,
    "isdelete": 0,
    "addtime": "2021-06-25T18:40:54.3",
    "vid": 1
  },
  {
    "id": 7,
    "type": 1,
    "title": "SHR-1316",
    "subtitle": "Anti-PD-L1 Antibody",
    "chinalevel": 4,
    "globallevel": 1,
    "remarks": "In many types of human tumors, programmed cell death ligand 1 (PD-L1) is highly expressed. Such high expression is often associated with poor prognosis. \r\n\r\nSHR-1316 is a humanized IgG4 monoclonal antibody that binds specifically to human PD-L1, thereby interrupting the interaction of PD-L1 with PD-1 and B7-1 receptors. SHR-1316 is being developed for the treatment of solid tumors and hematologic malignancies. It demonstrated competitive anti-tumor efficacy and safety profiles in pre-clinical studies, as well as a desirable CMC profile. \r\n\r\nThe NDA of SHR-1316 in combination with chemotherapy for SCLC has been filed to NMPA. A phase I trial for solid tumors is ongoing in Australia. ",
    "idx": 9950,
    "isdelete": 0,
    "addtime": "2021-06-25T18:45:44.183",
    "vid": 1
  },
  {
    "id": 8,
    "type": 1,
    "title": "SHR3680",
    "subtitle": "AR Antagonist",
    "chinalevel": 5,
    "globallevel": 3,
    "remarks": "Androgen receptor (AR) is a ligand-dependent transcription factor. AR overexpression is identified as a frequent driver of castration-resistant prostate cancer (CRPC). AR plays a critical role in cell growth in CRPC despite low serum androgen levels. \r\n\r\nSHR3680 is a second-generation full AR antagonist for prostate cancer without agonistic activity. It has shown promising efficacy in the control of bone metastasis, soft tissue lesions, and PSA level in phase I/II trial. Currently, a head-to-head phase III trial of SHR3680 + ADT vs bicalutamide + ADT for metastatic hormone-sensitive prostate cancer (mHSPC) is ongoing in China and Europe. Two phase II trials for mCRPC are ongoing in China. ",
    "idx": 9940,
    "isdelete": 0,
    "addtime": "2021-06-25T18:46:14.97",
    "vid": 1
  },
  {
    "id": 9,
    "type": 1,
    "title": "SHR1020 (famitinib)",
    "subtitle": "VEGFR2/c-Kit/PDGFR",
    "chinalevel": 3,
    "globallevel": 0,
    "remarks": "Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as major targets for drug discovery. Famitinib is a novel, multi-targeted receptor tyrosine kinase inhibitor with potential antineoplastic activity that primarily targets VEGFR2, c-Kit, and PDGFR.\r\n\r\nA phase III clinical trial of famitinib for gastrointestinal stromal tumors and another phase III trial of famitinib in combination with camrelizumab (anti-PD-1 antibody) and chemotherapy for NSCLC are ongoing in China. ",
    "idx": 9920,
    "isdelete": 0,
    "addtime": "2021-06-25T18:47:05.587",
    "vid": 1
  },
  {
    "id": 10,
    "type": 1,
    "title": "SHR6390 (dalpiciclib)",
    "subtitle": "CDK4/6 Inhibitor",
    "chinalevel": 5,
    "globallevel": 0,
    "remarks": "Cyclin-dependent kinases 4 and 6 (CDK4/6) are key components of cell cycle progression and are dysregulated in certain cancers. Inhibition of CDK4/6 induces cell cycle arrest at the G1 phase, thus retards tumor growth. SHR6390 is a novel CDK4/6 inhibitor. SHR6390 received the marketing approval in China for the 2L treatment of HR+/HER2- locally advanced or metastatic breast cancer in combination with fulvestrant in January 2022.",
    "idx": 9910,
    "isdelete": 0,
    "addtime": "2021-06-25T18:47:42.327",
    "vid": 1
  },
  {
    "id": 11,
    "type": 1,
    "title": "SHR-1701",
    "subtitle": "Bifunctional fusion protein targeting  PD-L1 and TGF-β",
    "chinalevel": 3,
    "globallevel": 1,
    "remarks": "Secretion of TGF-β and upregulation of immune checkpoint PD-L1 are two main contributors to immune evasion and tumor progression. SHR-1701 is an investigational bi-functional fusion protein composed of a mAb against PD-L1 fused to the extracellular domain of human TGF-β receptor II, designed to simultaneously block the two immunosuppressive signaling pathways commonly used by cancer cells. \r\n\r\nSHR-1701 is currently in phase II for unresectable stage III NSCLC and pancreatic cancer in China. A global phase I clinical trial for advanced solid tumors is ongoing in China and Australia.\r\n\r\nIn November 2020, Hengrui Pharma licensed the Korean rights of SHR-1701 to DONG-A ST CO., Ltd who now has exclusive rights to conduct clinical development, manufacture, and pursue commercialization licenses in the Republic of Korea.",
    "idx": 9900,
    "isdelete": 0,
    "addtime": "2021-06-25T18:48:15.27",
    "vid": 1
  },
  {
    "id": 13,
    "type": 1,
    "title": "SHR-1501",
    "subtitle": "IL-15 and IL-15 Rα/Fc Fusion Protein",
    "chinalevel": 1,
    "globallevel": 0,
    "remarks": "IL-15 induces proliferation and activation of natural killer cells and CD8+ T cells to activate both innate and adaptive immunity to enhance patients’ immune response against the tumor. Meanwhile, IL-15 neither stimulates Treg proliferation, nor promotes activation-induced T-cell death. \r\n\r\nSHR-1501 is an IL-15 super-agonist to boost the immune system. SHR-1501 features extended half-life via a unique Fc fusion design and improved stability by cross linking IL-15 with IL-15Rα Sushi domain through a disulfide bond. And another phase I trial of SHR-1501 monotherapy is also ongoing in China.",
    "idx": 9880,
    "isdelete": 0,
    "addtime": "2021-06-25T18:53:45.48",
    "vid": 1
  },
  {
    "id": 14,
    "type": 1,
    "title": "SHR-A1811",
    "subtitle": "HER2 ADC",
    "chinalevel": 3,
    "globallevel": 1,
    "remarks": "SHR-A1811 is an innovative HER2-targeted antibody-drug conjugate with a bystander payload conjugated to an anti-HER-2 mAb by a cleavable linker. Once bound to HER2 expressing tumor cells, the ADC is internalized and the linker releases the toxin, leading to tumor cell death.\r\n\r\nA global phase I clinical trial for advanced solid tumor is ongoing in China, US, Japan, Australia and the Republic of Korea. A phase I/II clinical trial for advanced NSCLC is ongoing in China",
    "idx": 9870,
    "isdelete": 0,
    "addtime": "2021-06-25T18:54:23.397",
    "vid": 1
  },
  {
    "id": 16,
    "type": 1,
    "title": "SHR1459",
    "subtitle": "BTK Inhibitor",
    "chinalevel": 2,
    "globallevel": 1,
    "remarks": "Bruton's tyrosine kinase (BTK) is an essential component of the BCR signaling pathway. Inhibition of BTK has been demonstrated to be an effective treatment for B-cell malignancies and autoimmune diseases.\r\n\r\nSHR1459 is a novel, orally available, and covalently-bound BTK inhibitor that exhibits unique pharmacologic properties compared with other BTK inhibitors. SHR1459 is currently under phase I clinical development for Mature B Cell Neoplasms in China. A global phase I clinical trial for B-cell Malignancy is ongoing in Australia and EU.\r\n\r\nIn January 2018, TG Therapeutics licensed from Hengrui Pharma worldwide rights, excluding Asia but including Japan, for the development and commercialization of SHR1459 for hematological indications. ",
    "idx": 9850,
    "isdelete": 0,
    "addtime": "2021-06-25T18:56:22.697",
    "vid": 1
  },
  {
    "id": 29,
    "type": 3,
    "title": "SHR0302",
    "subtitle": "JAK1 Inhibitor",
    "chinalevel": 3,
    "globallevel": 3,
    "remarks": "JAK-STAT signaling pathway involves in the production of multiple inflammatory cytokines in the pathological processes of autoimmune diseases.\r\n\r\nSHR0302 is a clinical-stage JAK1 inhibitor being developed to address multiple diseases.\r\n\r\nSHR0302 is currently in phase III clinical development for the treatment of ulcerative colitis in the US, EU and China. Another phase III clinical trial for atopic dermatitis is being conducted in Canada by Arcutis. Two phase II clinical trials of SHR0302 are ongoing globally for alopecia areata and crohn's disease repectively. Besides, SHR0302 is being studied in phase III and phase II clinical trials for a few more indications in China.\r\n\r\nOn Jan 5th 2018, Arcutis obtained the US, EU, and Japan rights for the development of topical SHR0302 for dermatology disorders from Hengrui Pharma. ",
    "idx": 7980,
    "isdelete": 0,
    "addtime": "2021-06-25T19:07:32.737",
    "vid": 1
  },
  {
    "id": 30,
    "type": 3,
    "title": "SHR-1314 (vunakizumab)",
    "subtitle": "Anti-IL-17 Antibody",
    "chinalevel": 3,
    "globallevel": 0,
    "remarks": "Interleukin 17 (IL-17) is a pro-inflammatory cytokine, which is associated with numerous immune regulatory functions. IL-17 inhibitors are being investigated as possible treatments for autoimmune disease, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. \r\n\r\nVunakizumab, a clinical-stage humanized monoclonal lgG1 antibody, targets both human IL-17A homodimer and IL-17A/F heterodimer to address autoimmune diseases. \r\n\r\nFour phase I clinical trials in China or Australia and one global phase I/II clinical trial were completed. Two phase I clinical trials, one phase II/III clinical trial, and one phase III clinical trial are ongoing in China. One phase II clinical trial for psoriasis is ongoing in the US and Australia. ",
    "idx": 7970,
    "isdelete": 0,
    "addtime": "2021-06-25T19:08:12.117",
    "vid": 1
  },
  {
    "id": 31,
    "type": 3,
    "title": "SHR4640",
    "subtitle": "URAT1 Inhibitor",
    "chinalevel": 3,
    "globallevel": 0,
    "remarks": "Hyperuricemia and gout are metabolic diseases caused by chronic elevation of serum uric acid levels. Uric acids in the renal tubules are re-absorbed into the body by uric acid transporter 1 (URAT1). Inhibition of URAT1 increases urinary excretion of uric acid. \r\n\r\nSHR4640 is a selective inhibitor of URAT1 being developed as an oral, once-daily treatment for the chronic management of hyperuricemia in patients with gout. \r\n\r\nSHR4640 is currently in phase III stage in China and a phase I clinical trial is also ongoing in Australia.",
    "idx": 7960,
    "isdelete": 0,
    "addtime": "2021-06-25T19:08:47.79",
    "vid": 1
  },
  {
    "id": 36,
    "type": 4,
    "title": "SHR0410",
    "subtitle": "KOR Agonist",
    "chinalevel": 3,
    "globallevel": 0,
    "remarks": "The κ-opioid receptor (KOR) is a type of opioid receptor that binds the opioid peptide dynorphin as the primary endogenous ligand. KOR agonists are potently analgesic, and have been employed clinically in the treatment of pain.\r\n\r\nSHR0410 is a novel KOR agonist currently in phase III development for the treatment of pain after endoscopic surgery of the lower abdominal and phase I development for the treatment of pruritus in hemodialysis patients in China. A phase I trial for analgesia and pruritus is ongoing in Australia. ",
    "idx": 6960,
    "isdelete": 0,
    "addtime": "2021-06-25T19:35:29.923",
    "vid": 1
  },
  {
    "id": 37,
    "type": 5,
    "title": "SHR8008 (VT-1161)",
    "subtitle": "Fungal CYP51 Inhibitor",
    "chinalevel": 4,
    "globallevel": 3,
    "remarks": "CYP51 is required for the biosynthesis of lanosterol, a key component of the fungal cell membrane. And it has become a favorable drug target for diseases caused by Candida infection such as vulvovaginal Candidiasis (VVC). While there are some effective antifungal agents, they have raised some safety issues due to off-target effects. SHR8008 is designed to be more selective for the fungal enzyme CYP51 than related human CYP enzymes such as CYP3A4, therefore reducing side effects.\r\n\r\nA phase III clinical trial of SHR8008 for VVC and a phase II clinical trial for recurrent vulvovaginal candidiasis (RVVC) are ongoing in China. \r\n\r\nIn June 2019, Hengrui Pharma entered into an exclusive licensing agreement with Mycovia to develop and commercialize VT-1161 for the treatment or prevention of a range of fungal conditions, including RVVC, onychomycosis, and invasive fungal infections. A phase III clinical trial for RVVC run by Mycovia is ongoing in the US, Canada, EU and Japan.",
    "idx": 5990,
    "isdelete": 0,
    "addtime": "2021-06-25T19:52:03.773",
    "vid": 1
  },
  {
    "id": 40,
    "type": 6,
    "title": "SHR8028",
    "subtitle": "CyclASol®, 0.1% cyclosporine A",
    "chinalevel": 3,
    "globallevel": 3,
    "remarks": "In November 2019, Hengrui Pharma entered into an exclusive licensing agreement with Novaliq GmbH, a Germany-based pharmaceutical company, to develop and commercialize Novaliq's patented investigational products, SHR8028 (CyclASol®, 0.1% cyclosporine A)  and SHR8058 (NOV03, perfluorohexyloctane) for the treatment of ophthalmic diseases including Dry Eye Disease (DED).\r\n\r\nSHR8028 is currently in phase III development for the treatment of DED with an inflammatory disease component in China and the US. ",
    "idx": 4990,
    "isdelete": 0,
    "addtime": "2021-06-25T19:54:06.397",
    "vid": 1
  },
  {
    "id": 44,
    "type": 6,
    "title": "SHR8058 ",
    "subtitle": "NOV03, perfluorohexyloctane",
    "chinalevel": 3,
    "globallevel": 3,
    "remarks": "In November 2019, Hengrui Pharma entered into an exclusive licensing agreement with Novaliq GmbH, a Germany-based pharmaceutical company, to develop and commercialize Novaliq's patented investigational products, SHR8028 (CyclASol®, 0.1% cyclosporine A)  and SHR8058 (NOV03, perfluorohexyloctane) for the treatment of ophthalmic diseases including Dry Eye Disease (DED).\r\nSHR8058 is a semi fluorinated alkane being developed in phase III for the treatment of DED associated with Meibomian gland dysfunction (MGD) in China and the US.",
    "idx": 4980,
    "isdelete": 0,
    "addtime": "2021-06-29T11:01:21.327",
    "vid": 1
  },
  {
    "id": 42,
    "type": 6,
    "title": "SHR-1707",
    "subtitle": "Anti-Aβ Antibody",
    "chinalevel": 1,
    "globallevel": 1,
    "remarks": "Accumulation of amyloid-β (Aβ) peptide has been recognized as a core pathology in Alzheimer’s Disease (AD). The imbalance between production and clearance of Aβ can be a very early, often initiating factor of AD. Thus, anti-Aβ therapeutic approaches have been extensively studied in the past few decades as disease-modifying treatments for AD\r\n\r\nSHR-1707 is a novel anti-Aβ monoclonal antibody currently under phase I development in Australia.",
    "idx": 4960,
    "isdelete": 0,
    "addtime": "2021-06-25T19:55:10.32",
    "vid": 1
  },
  {
    "id": 4,
    "type": 1,
    "title": "Mecapegfilgrastim",
    "subtitle": "Long-Acting PEG-rhG-CSF ",
    "chinalevel": 5,
    "globallevel": 0,
    "remarks": "Neutropenia is a common adverse effect for as many as one in three patients receiving chemotherapy. Granulocyte-colony stimulating factor (G-CSF) stimulates the production of granulocytes, including neutrophils. In oncology and hematology, a recombinant form of G-CSF is used to accelerate recovery and reduce mortality from neutropenia associated with chemotherapy, allowing higher adherence to the prescribed chemotherapy regimens.\r\n\r\nMecapegfilgrastim is a novel PEGylated human recombinant G-CSF that enables once per chemotherapy cycle injection, rather than daily injection. A total of five completed/ongoing clinical trials (including one Ia trial in healthy volunteers) among NSCLC and breast cancer patients have fully validated mecapegfilgrastim’s superior ability to reduce neutropenia.\r\n\r\nMecapegfilgrastim received marketing approval in China in July 2018. ",
    "idx": 1000,
    "isdelete": 0,
    "addtime": "2021-06-25T17:04:38.253",
    "vid": 1
  },
  {
    "id": 6,
    "type": 1,
    "title": "Apatinib",
    "subtitle": "VEGFR2 inhibitor",
    "chinalevel": 5,
    "globallevel": 0,
    "remarks": "Vascular endothelial growth factor receptors (VEGFR) are a family of receptor tyrosine kinases, which play an important role in both vasculogenesis and angiogenesis. Among all subtypes, sVEGFR inhibitors were approved for oncology treatment, and more molecules are under development. \r\n\r\nApatinib is a selective VEGFR-2 inhibitor which also mildly inhibits c-Kit and c-Src tyrosine kinases. It is the first approved small-molecule targeted therapy for late-stage gastric cancer in the world, with good efficacy and safety profiles demonstrated in both pre- and post-marketing studies.\r\n\r\nApatinib is marketed in China in 2014. A global phase III clinical study of camrelizumab (anti-PD-1 antibody) plus apatinib vs. sorafenib as the first-line therapy for advanced hepatocellular carcinoma (HCC) is ongoing.",
    "idx": 990,
    "isdelete": 0,
    "addtime": "2021-06-25T18:44:33.433",
    "vid": 1
  },
  {
    "id": 12,
    "type": 1,
    "title": "HRS-3536 (Linperlisib)",
    "subtitle": "PI3Kδ Inhibitor",
    "chinalevel": 4,
    "globallevel": 0,
    "remarks": "Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling is one of the most important intracellular pathways, which regulates cell growth, motility, survival, metabolism, and angiogenesis. Hyperactivation of PI3K/AKT pathway contributes to various human cancers.\r\n\r\nHRS-3536 is an orally available inhibitor selectively targets PI3K subunit delta to prevent the activation of the PI3K/AKT signaling pathway. Such targeted inhibition induces cell death in PI3Kδ over-expressing cells while preserving PI3K signaling in non-neoplastic cells, thereby minimizing serious side effects. HRS-3536 is currently under NDA review in China. FDA granted Orphan Drug Designation to HRS-3536 to treat follicular lymphoma (FL) and chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). NMPA granted Breakthrough Therapy Designation to HRS-3536 to treat r/r FL.\r\n\r\nIn February 2021, Hengrui Pharma entered into a strategic agreement with Yingli Pharma. Hengrui Pharma obtained joint development rights and exclusive rights for commercializing HRS-3536 in China. ",
    "idx": 980,
    "isdelete": 0,
    "addtime": "2021-06-25T18:51:50.61",
    "vid": 1
  },
  {
    "id": 15,
    "type": 1,
    "title": "SHR2554",
    "subtitle": "EZH2 inhibitor ",
    "chinalevel": 1,
    "globallevel": 0,
    "remarks": "Enhancer of zeste homologue 2 (EZH2) is an enzymatic subunit of polycomb repressive complex 2 (PRC2), which silences tumor suppressor genes in cancer cells. Selective inhibition of histone methyltransferase EZH2 downregulates the methylation of H3K27, reducing tumor cell proliferation. \r\n\r\nSHR2554 inhibits the wild-type and mutated histone methyltransferase EZH2, preventing the methylation of H3K27. As a result, it alters gene expression patterns associated with cancer pathways and decreases tumor cell proliferation in EZH2 mutated cancer cells. SHR2554 is currently under phase I clinical development for relapsed or refractory mature lymphoid neoplasms.",
    "idx": 970,
    "isdelete": 0,
    "addtime": "2021-06-25T18:55:17.917",
    "vid": 1
  },
  {
    "id": 17,
    "type": 1,
    "title": "Anti-TIM-3 Antibody",
    "subtitle": "",
    "chinalevel": 1,
    "globallevel": 0,
    "remarks": "T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) functions as a T-cell inhibitory receptor to limit the duration and magnitude of Th1 and Tc1 T-cell response. The blockage of TIM-3 knocks out the immune suppression in tumor tissues, restoring function of disabled CD8+ T cells. Anti-TIM-3 antibody has also showed a potential synergy with anti-PD-1 antibody.\r\n\r\nA novel anti-TIM-3 antibody is under development by Hengrui for the treatment of solid tumors and hematological malignancies. A phase I clinical trial of the antibody as monotherapy in relapsed/refractory AML and intermediate-high risk MDS is ongoing.",
    "idx": 960,
    "isdelete": 0,
    "addtime": "2021-06-25T18:57:09.283",
    "vid": 1
  },
  {
    "id": 18,
    "type": 1,
    "title": "SHR-1802",
    "subtitle": "Anti-LAG-3 Antibody",
    "chinalevel": 2,
    "globallevel": 0,
    "remarks": "Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint receptor protein found on the cell surface of effector T cells and regulatory T cells (Tregs) and functions to control T cell response, activation and growth. In cancer, LAG-3 expressing exhausted cytotoxic T cells and Tregs expressing LAG-3 gather at tumor sites. Inhibition of LAG-3 could potentially restore the active antitumor activity of T cells.\r\n\r\nSHR-1802 is a mAb specific for LAG-3 and is currently under phase I clinical development stage for malignant tumors.",
    "idx": 950,
    "isdelete": 0,
    "addtime": "2021-06-25T18:57:48.9",
    "vid": 1
  },
  {
    "id": 19,
    "type": 1,
    "title": "PEG-IL-2",
    "subtitle": "",
    "chinalevel": 1,
    "globallevel": 0,
    "remarks": "Interleukin-2 (IL-2) is a cytokine that plays an important role in the preservation of T cell homeostasis and proper immune regulation. It has been studied for a long time as an immunotherapy and has shown great efficacy in treating several cancers. Hengrui has developed a novel polyethylene glycol conjugated human recombinant cytokine IL-2 that induces antineoplastic activity.  \r\n\r\nThe drug candidate is currently under phase I clinical development stage for solid tumors.",
    "idx": 940,
    "isdelete": 0,
    "addtime": "2021-06-25T18:58:27.55",
    "vid": 1
  },
  {
    "id": 20,
    "type": 2,
    "title": "Retagliptin",
    "subtitle": "DPP-4 Inhibitor",
    "chinalevel": 4,
    "globallevel": 0,
    "remarks": "GLP-1 and GIP are incretins that regulate blood glucose levels by increasing insulin release and decreasing glucagon secretion. Dipeptidyl peptidase 4 (DPP-4) is an enzyme that degrades GLP-1 and GIP. The inhibition of DPP-4 preserves the functions of GLP-1 and GIP to control the blood glucose level. \r\n\r\nRetagliptin is an NDA-stage DPP-4 inhibitor for the treatment of type 2 diabetes. In completed phase II trials, retagliptin monotherapy or in combination with metformin significantly decreased the HbA1c level in type 2 diabetic patients. ",
    "idx": 930,
    "isdelete": 0,
    "addtime": "2021-06-25T18:59:42.733",
    "vid": 1
  },
  {
    "id": 22,
    "type": 2,
    "title": "SHR20004",
    "subtitle": "GLP-1 Receptor Agonist",
    "chinalevel": 2,
    "globallevel": 0,
    "remarks": "Glucagon-like peptide-1 (GLP-1) is one of incretins that increases insulin secretion and inhibits glucagon release when glucose levels are elevated. GLP-1 is an important target for metabolic disease. type 2 diabetes since it has the potential of decreasing plasma glucose levels with low risk of hypoglycemia. \r\n\r\nSHR20004 is a phase II-stage subcutaneous injectable GLP-1 receptor agonist for metabolic diseases. ",
    "idx": 920,
    "isdelete": 0,
    "addtime": "2021-06-25T19:02:56.227",
    "vid": 1
  },
  {
    "id": 23,
    "type": 2,
    "title": "SHR-1209",
    "subtitle": "Anti-PCSK9 Antibody",
    "chinalevel": 3,
    "globallevel": 0,
    "remarks": "Proprotein convertase subtilin/kexin type 9 (PCSK9) binds to low-density lipoprotein receptors (LDLR), enhancing the lysosomal degradation of LDLR. The blockage of PCSK9 increases LDLR recycling; therefore, more LDLRs are present on the cell membranes to uptake LDL into cells. As a result, PCSK9 blockage decreases blood LDL concentrations.\r\n\r\nSHR-1209 is a PCSK9 inhibitor being developed for hypercholesterolemia. SHR-1209 is currently under phase III development in China.",
    "idx": 910,
    "isdelete": 0,
    "addtime": "2021-06-25T19:03:35.56",
    "vid": 1
  },
  {
    "id": 21,
    "type": 2,
    "title": "SHR3824  (henagliflozin)",
    "subtitle": "SGLT2 Inhibitor",
    "chinalevel": 5,
    "globallevel": 0,
    "remarks": "Sodium-glucose transport protein 2 (SGLT2) is the major co-transporter responsible for 90% of glucose reabsorption in the kidney. The inhibition of SGLT2 decreases blood glucose levels by reducing urine glucose reabsorption and increasing glucose excretion. \r\n\r\nSHR3824 is an approved SGLT2 inhibitor for the treatment of type 2 diabetes. In completed phase II trials, SHR3824 monotherapy or in combination with metformin effectively decreased the HbA1c, FPG, 2h PPG, body weight, and blood pressure in type 2 diabetes patients. \r\n\r\nTwo phase III trials for SHR3824 monotherapy and in combination with metformin were completed in China. ",
    "idx": 900,
    "isdelete": 0,
    "addtime": "2021-06-25T19:02:13",
    "vid": 1
  },
  {
    "id": 24,
    "type": 2,
    "title": "INS068",
    "subtitle": "Long-Acting Basal Insulin",
    "chinalevel": 2,
    "globallevel": 2,
    "remarks": "In patients with diabetes, the destruction or dysfunction of beta cells of pancreatic islets results in less secretion of insulin, and thus leads to high blood glucose levels. Administration of basal insulin helps diabetic patients to maintain a needed level of insulin and to keep their blood glucose in stable levels during fasting period. \r\n\r\nINS068 is a long-acting basal insulin currently under phase II clinical development for Type 2 Diabetes in China, US and Australia.",
    "idx": 890,
    "isdelete": 0,
    "addtime": "2021-06-25T19:04:11.45",
    "vid": 1
  },
  {
    "id": 26,
    "type": 2,
    "title": "SHR7280",
    "subtitle": " GnRH Antagonist",
    "chinalevel": 3,
    "globallevel": 0,
    "remarks": "Endometriosis is an estrogen-dependent disease that is treatable by estrogen withdrawal. Gonadotropin-releasing hormone antagonists (GnRH antagonists) could bind to GnRH receptor, and thus inhibit the synthesis and release of gonadotropins, and therefore decrease the levels of estrogens and androgens. GnRH antagonists have been developed to treat endometriosis and fibroids. \r\n\r\nSHR7280 is an oral GnRH antagonist that competitively binds to GnRH receptor. A phase I/II clinical trial for the treatment of endometriosis is ongoing in China.",
    "idx": 870,
    "isdelete": 0,
    "addtime": "2021-06-25T19:05:18.573",
    "vid": 1
  },
  {
    "id": 27,
    "type": 2,
    "title": "Factor XI (FXI) Antagonist",
    "subtitle": "",
    "chinalevel": 1,
    "globallevel": 1,
    "remarks": "FXI is a central player in thrombin generation in the amplification phase and may lead to overexpression of thrombin with excessive clots formation resulting in pathologic thrombosis. It has become a favorable antithrombotic drug target because selective inhibition of FXI would leave the extrinsic and common pathways of coagulation intact and therefore have less impact on hemostasis.\r\n\r\nA novel FXI antagonist developed by Hengrui is currently at phase I clinical stage. ",
    "idx": 860,
    "isdelete": 0,
    "addtime": "2021-06-25T19:06:04.66",
    "vid": 1
  },
  {
    "id": 28,
    "type": 3,
    "title": "Hetrombopag",
    "subtitle": " Thrombopoietin Receptor Agonist ",
    "chinalevel": 5,
    "globallevel": 1,
    "remarks": "Thrombopotetin regulates the production of platelets by activation of the thrombopoietin receptor (TPOR). TPOR agonists are novel treatments for thrombocytopenia.\r\n\r\nHetrombopag is a TPO receptor agonist approved in China in 2021 for idiopathic thrombocytopenic purpura (ITP) and second line severe aplastic anemia (SAA).The indications of chemotherapy-induced thrombocytopenia (CIT), pediatric/juvenile ITP and naïve severe aplastic anemia are under development. A phase I trial is ongoing in Australia.",
    "idx": 850,
    "isdelete": 0,
    "addtime": "2021-06-25T19:06:57.72",
    "vid": 1
  },
  {
    "id": 32,
    "type": 3,
    "title": "SHR-1703",
    "subtitle": " Anti-IL-5 Antibody",
    "chinalevel": 1,
    "globallevel": 0,
    "remarks": "Interleukin-5 (IL-5) exerts a central pathogenic role in differentiation, recruitment, survival, and degranulation of eosinophils. Many patients with severe asthma express a type 2 (T2)-high phenotype featured by eosinophilic inflammation. Biologic agents targeting IL-5 have shown effects in reducing the rate of asthma exacerbations\r\n\r\nSHR-1703 is a mAb of IL-5 currently under phase I development stage in China and Australia.",
    "idx": 840,
    "isdelete": 0,
    "addtime": "2021-06-25T19:09:27.38",
    "vid": 1
  },
  {
    "id": 33,
    "type": 4,
    "title": "Imrecoxib",
    "subtitle": "COX-2 Inhibitor",
    "chinalevel": 5,
    "globallevel": 0,
    "remarks": "Cyclooxygenase (COX) is an enzyme that is responsible for production of prostanoids, including thromboxane and prostaglandins (PGs). PGs promote inflammation, pain, and fever. Selective COX-2 inhibitor is a subclass of NSAIDs, which inhibits the formation of PGs to reduce inflammation, pain, and fever. \r\n\r\nImrecoxib is a highly selective COX-2 inhibitor approved in China in 2011, which relieves the pain induced by osteoarthritis.",
    "idx": 830,
    "isdelete": 0,
    "addtime": "2021-06-25T19:33:04.187",
    "vid": 1
  },
  {
    "id": 34,
    "type": 4,
    "title": "Remimazolam",
    "subtitle": "Short-Lasting GABAα Receptor Agonist ",
    "chinalevel": 5,
    "globallevel": 0,
    "remarks": "Gamma-aminobutyric acid (GABA) is an important inhibitory neurotransmitter in mammalian central nervous system. Activation of GABA receptors results in neural inhibition, reducing neuronal excitability, sedation, and amnesia etc. \r\n\r\nRemimazolam is a short-lasting GABAα receptor agonist for anesthesia and conscious sedation for minor invasive procedures. Remimazolam is currently approved in China for the treatment of gastroscopy sedation and colonoscopy sedation. NDA was filed for the indication of general anesthesia and phase III clinical trial for the treatment of fibrobronchoscope sedation is ongoing.  ",
    "idx": 820,
    "isdelete": 0,
    "addtime": "2021-06-25T19:33:40.53",
    "vid": 1
  },
  {
    "id": 35,
    "type": 4,
    "title": "SHR8554",
    "subtitle": "MOR Agonist",
    "chinalevel": 3,
    "globallevel": 0,
    "remarks": "Opioid analgesics have been used for a long time in the treatment of pain and related disorders. The μ-opioid receptors (MOR) are a class of opioid receptors with a high affinity for enkephalins and beta-endorphin, but a low affinity for dynorphins. MOR can mediate acute changes in neuronal excitability via suppression of presynaptic release of GABA. \r\n\r\nSHR8554 is a selective biased μ-opioid receptor agonist which activates the \r\nMOR-mediated G-protein coupling, but barely recruits β-arrestin-2. It has demonstrated remarkable analgesic effects in a variety of acute pains with significant improvement in DI dysfunction. Two phase IIb/III trials for acute postoperative pain are ongoing in China.",
    "idx": 810,
    "isdelete": 0,
    "addtime": "2021-06-25T19:34:14.77",
    "vid": 1
  },
  {
    "id": 38,
    "type": 5,
    "title": "HRS9950",
    "subtitle": "TLR8 Inhibitor",
    "chinalevel": 1,
    "globallevel": 0,
    "remarks": "Toll-like receptor 8 (TLR8) is mainly expressed on the endosome of cells, which can recognize the single-stranded RNA of virus or bacterial and some small molecule ligands. In liver tissues infected by HBV, TLR8 agonists can induce IL-12 and IFN-γ cytokines through NF-κB and IRF signaling pathways, exerting direct antiviral effects. TLR8 agonists can also indirectly activate adaptive immunity, by increasing the antigen presentation function of DC cells, promoting the differentiation and maturation process of liver lymphatic B cells and T cells, further killing viruses that infect liver cells.\r\n\r\nHRS9950 is a novel small molecule selectively targeting TLR8, with potential to stimulate adaptive immune responses and cure chronic hepatitis B (CHB). One phase I multi-center basket trial is ongoing, and more trials are under planning. ",
    "idx": 800,
    "isdelete": 0,
    "addtime": "2021-06-25T19:52:40.72",
    "vid": 1
  },
  {
    "id": 39,
    "type": 5,
    "title": "HRS5091",
    "subtitle": "HBV Core Protein Inhibitor ",
    "chinalevel": 1,
    "globallevel": 0,
    "remarks": "Hepatitis B virus (HBV) core protein (HBc) plays important roles in viral life cycle, especially in capsid assembly. HRS5091 is an oral, class II, selective HBV capsid inhibitor with pan-genotypic activity. It interferes the uncoating process of nucleocapsid, which inhibits the formation of covalently closed circular DNA (cccDNA).\r\n\r\nA phase I clinical trial is ongoing in China, and more trials are under planning.",
    "idx": 790,
    "isdelete": 0,
    "addtime": "2021-06-25T19:53:18.34",
    "vid": 1
  },
  {
    "id": 41,
    "type": 6,
    "title": "SHR-1222",
    "subtitle": "Anti-SOST Antibody",
    "chinalevel": 1,
    "globallevel": 0,
    "remarks": "Sclerostin is a glycoprotein inhibitor of osteoblast Wnt signaling produced by osteocytes. Research studies found that mutations of the sclerostin gene SOST are associated with high bone mass, which suggested that inhibitors of sclerostin might be used to increase bone mineral density and could therefore be developed as therapeutic intervention in patients with osteoporosis.  \r\n\r\nSHR-1222 is a novel SOST monoclonal antibody currently under phase I development.",
    "idx": 780,
    "isdelete": 0,
    "addtime": "2021-06-25T19:54:39.377",
    "vid": 1
  }
];
                 binddata(data,"#tab1");
               
			

			})

          

			function binddata(data,_id)
			{

                var html = '';
                var linelevel = [];
                for (var i = 0; i < data.length; i++) {

                    var t1 = data[i];

                    linelevel.push({ data: ['', '', '', '', ''], index: t1.chinalevel - 1 });
                    linelevel.push({ data: ['', '', '', '', ''], index: t1.globallevel - 1 });
                    var t2 = null;
                    if (i + 1 < data.length) {
                        t2 = data[i + 1]
                        linelevel.push({ data: ['', '', '', '', ''], index: t2.chinalevel - 1 });
                        linelevel.push({ data: ['', '', '', '', ''], index: t2.globallevel - 1 });
                        i++;
                    }
                    html += ' <div class="row10 cf pipSeeLis mo_row">';
                    html += '  <div class="area_50 padding10 pipSeeChile">';
                    html += '       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick=showlis(this)>';
                    html += '				<span class="dis cf">';
                    html += '          <h4 class="fleft">' + t1.title + '</h4>';
                    html += '           <i class="fright iconfont icon-jt fa-1_6x"></i>';
                    html += '      </span>';
                    html += '      <p class="fontSize12 paddingtop10">' + t1.subtitle + '</p>';
                    html += '				</a>';
                    html += '   <div class="padding20 bgfff miin-height">';
                    html += '       <div class="cf">';
                    html += '          <div class="cadeProcess marginauto">';
                    html += '              <p class="area_20">I</p>';
                    html += '              <p class="area_20">II</p>';
                    html += '             <p class="area_20">III</p>';
                    html += '              <p class="area_20">NDA</p>';
                    html += '             <p class="area_20">Launched</p>';
                    html += '          </div>';
                    html += '      </div>';
                    
                    html += '       <div class="pipStep cf positionRelative  ' + (t1.chinalevel == 0?"undis":"")+'">';
                    html += '           <p class="area_10 poabsolute-h50">China</p>';
                    html += '          <div class="perSteps width90 fright"></div>';
                    html += '      </div>';
                    html += '      <div class="globalStep cf positionRelative ' + (t1.globallevel == 0 ? "undis" : "") + '">';
                    html += '         <p class="area_10 poabsolute-h50">Global</p>';
                    html += '          <div class="perSteps width90 fright"></div>';
                    html += '     </div>';
                    html += '  </div>';
                    html += '   <div class="mo_dis">';
                    html += '       <div class="pipShowlis paddingtop20 positionRelative">';
                    html += '         <div class="triangle-up"></div>';
                    html += '          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20">' + t1.remarks.replace(/\n/g, "<br>") + '</p><div class="pipPack paddingtop20"><a class="dis tcenter color999999 paddingtop20" onclick=pipClose(<i class="iconfont icon-sjt fa-0_6x"></i></a></div></div>';
                    html += '  </div>';
                    html += '</div>';
                    html += '		</div>';
                    if (t2 != null) {
                        html += '   <div class="area_50 padding10 pipSeeChile">';
                        html += '       <a class="dis padding20 bg1e55a8 pipCade colorfff" onclick=showlis(this,2)>';
                        html += '				<span class="dis cf">';
                        html += '           <h4 class="fleft">' + t2.title + '</h4>';
                        html += '          <i class="fright iconfont icon-jt fa-1_6x"></i>';
                        html += '      </span>';
                        html += '      <p class="fontSize12 paddingtop10">' + t2.subtitle + '</p>';
                        html += '			</a>';
                        html += '  <div class="padding20 bgfff miin-height">';
                        html += '      <div class="cf">';
                        html += '          <div class="cadeProcess marginauto">';
                        html += '              <p class="area_20">I</p>';
                        html += '            <p class="area_20">II</p>';
                        html += '            <p class="area_20">III</p>';
                        html += '            <p class="area_20">NDA</p>';
                        html += '             <p class="area_20">Launched</p>';
                        html += '           </div>';
                        html += '      </div>';
                        html += '       <div class="pipStep cf positionRelative  ' + (t2.chinalevel == 0 ? "undis" : "") + '">';
                        html += '           <p class="area_10 poabsolute-h50">China</p>';
                        html += '          <div class="perSteps width90 fright"></div>';
                        html += '      </div>';
                        html += '      <div class="globalStep cf positionRelative  ' + (t2.globallevel == 0 ? "undis" : "") + '">';
                        html += '         <p class="area_10 poabsolute-h50">Global</p>';
                        html += '          <div class="perSteps width90 fright"></div>';
                        html += '     </div>';
                        html += '  </div>';
                        html += '  <div class="mo_dis">';
                        html += '     <div class="pipShowlis paddingtop20 positionRelative">';
                        html += '          <div class="triangle-up"></div>';
                        html += '          <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> ' + t2.remarks.replace(/\n/g, "<br>")  + '</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick=pipClose(<i class="iconfont icon-sjt fa-0_6x"></i></a></div></div>';
                        html += '  </div>';
                        html += '			</div>';
                        html += '		</div >';

                    }
                    html += '  <div class="mo_undis">';
                    html += '      <div class="area_100 pipShowlis padding10 positionRelative">';
                    html += '         <div class="triangle-up"></div>';
                    html += '         <div class="padding20 bgfff positionRelative zindex2"><p class="fontSize12 paddingtop20"> Hengrui licensed the Korean rights of camrelizumab to CrystalGenomics Inc.</p><div class="pipPack paddingtop20"><a class="dis tcenter paddingtop20 color999999" onclick=pipClose(<i class="iconfont icon-sjt fa-0_6x"></i></a></div></div>';
                    html += '  </div>';
                    html += '		</div>';
                    html += '	</div >';


                }

				$(_id).html(html);
                console.log(linelevel);
                $(_id).find('.perSteps').each(function (i, o) {
                    $(o).stepInit(linelevel[i]);
                })

				$(_id).find(".pipShowlis").fadeOut(300);


			}

            /*--------------进度条--------------*/

            AOS.init({
                disable: window.innerWidth < 800,
                duration: 1000,
                once: true
			});





		</script>
	
	

 
 </body></html>